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ROLE OF P300 ZZ DOMAIN IN CHROMATIN ASSOCIATION AND HISTONE 
ACETYLATION 
 
Yongming Xue, B.S. 
Advisory Professor: Xiaobing Shi, Ph.D. 
 
Transcription is strictly regulated by numerous factors including transcription 
coactivators. The p300 protein and its close paralogue CREB-binding protein 
(CREBBP, aka CBP) are well-known transcriptional coactivators that have 
intrinsic lysine acetyltransferase activity. The functions of p300/CBP largely rely 
on their capabilities to bind to chromatin and to acetylate the histone substrates. 
However, the molecular mechanisms underlying the regulation of these 
processes are not fully understood.  
Through combination of various biochemical, biophysical and molecular 
approaches, we show that the ZZ-type zinc finger (ZZ) domain of p300 functions 
as a histone reader that specifically binds the N-terminal tail of histone H3. 
Crystal structure of p300 ZZ in complex with the H3 peptide reveals that the ZZ 
domain adopts a negatively charged cavity to anchor Ala1 and Arg2 of H3. The 
ZZ-H3 interaction is not sensitive to common post-translational modifications, 
such as methylation or acetylation, on the H3 tail. Both in vitro and cell-based 
assays reveal that p300 ZZ domain, together with bromodomain (BRD), is 
important in recruiting p300 to chromatin. As a module adjacent to the histone 
acetyltransferase (HAT) domain, ZZ domain is also required for efficient histone 
vii	
	
acetylation by HAT. The recognition of histone H3 by the ZZ domain selectively 
promotes p300-dependent acetylation specifically on histone H3K27 and H3K18, 
whereas the acetyllysine binding activity of BRD is required for acetylation of 
virtually all lysine residues in H3 and H4 tails. 
p300/CBP are frequently mutated or dysregulated in many human diseases 
including cancer. We found that p300 is overexpressed in small cell lung cancer 
(SCLC), the most aggressive subtype of lung cancer. By CRISPR/Cas9-
mediated gene manipulation, we found that p300 depletion impedes proliferation 
of human and mouse SCLC cells whereas CBP depletion has little or no effect. 
Depletion of p300 reduces the expression of critical oncogenes such as the MYC 
family genes, indicating that p300 promotes SCLC cell growth by sustaining 
oncogene expression.  
In summary, we identified the ZZ domain of p300 as a novel histone H3 
reader that is critical for the chromatin association and enzymatic activity of p300. 
Recognition of H3 by ZZ domain is important to the functions of p300 in human 
cancer.  
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Chapter 1. Introduction 
 
Copyright information: 
Contents of Chapter 1.1-1.3 are based on my review article: Xue Y*, Wen H, Shi 
X*. 2018. CBP/p300: intramolecular and intermolecular regulations. Front Biol. 
13: 168-179. (*: Corresponding authors). I am the primary author of this review. 
Permission to reuse the whole article for thesis was obtained from 
www.copyright.com with license number: 4456690546571. 
 
1.1 Transcriptional coactivators CBP/p300 
Transcription is critical for deciphering the commands encrypted in DNA 
for the completion of various important biological processes. Regulation of this 
molecular event in eukaryotes is complex, but strictly controlled by a vast 
network of regulatory factors. Two of these factors are cAMP response element-
binding protein (CREB)-binding protein (CREBBP, aka CBP or lysine 
acetyltransferase 3A, KAT3A) and its close paralogue p300 (aka KAT3B) (1, 2). 
CBP and p300 were initially identified as interacting proteins of CREB and 
adenoviral protein early region 1A (E1A), respectively (3-7). Both proteins contain 
intrinsic histone lysine acetyltransferase (HAT) activity (8, 9) and constitute the 
KAT3 family of acetyltransferase in mammals. The encoding genes of CBP and 
p300 in human genome are CREBBP and EP300, respectively. 
 Acetylation on histone lysine residues neutralizes positive charge on their 
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side chain, weakens not only the interaction between histones and negatively 
charged DNA but also that between neighboring nucleosomes, creating an open 
chromatin structure that facilitates transcription (10). CBP and p300 have 
promiscuous acetyltransferase activity. In vitro they are able to acetylate multiple 
sites of histones H2A, H2B, H3 and H4 in the context of free histone (8) or 
nucleosome (8, 9, 11).  However, depletion (12-14) or inhibition (14, 15) of both 
CBP and p300 in cells greatly reduces the global level of histone H3K18 and K27 
acetylation without dramatically affecting acetylation at other sites, indicating that 
they are mainly required for H3K18 and K27 acetylation in vivo. In response to 
DNA damage, CBP/p300 acetylate H3K56 on free histones (16, 17), which is 
required for chromatin reassembly after DNA repair (18). In addition to their 
histone substrates, CBP/p300 can also acetylate many other proteins including 
transcription factors (19). By interacting with hundreds of proteins, CBP and p300 
work as scaffolds to assemble transcriptional activation complexes, or serve as  
bridges linking the activator complexes to the RNA polymerase II (Pol II) 
transcription machinery (20-22). Consistent with their roles in transcriptional 
activation, CBP/p300 are mainly localized at regulatory DNA elements, especially 
enhancers (23, 24). In fact, the genomic occupancy of CBP/p300 has been used 
as a predictive marker for active enhancers (25). 
CBP and p300 proteins are composed of multiple conserved domains, 
which, from N- to C-terminus, include a nuclear receptor-interacting domain 
(NRID), a transcriptional adapter zinc-binding (TAZ1) domain, a kinase-inducible 
domain interacting (KIX) domain, a bromodomain (BRD), a combined Really 
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Interesting New Gene (RING) domain and plant homeodomain (PHD), a HAT 
domain that contains an autoinhibitory loop (AIL), a ZZ-type zinc finger (ZZ) 
domain, another TAZ domain (TAZ2) and an interferon binding domain (IBiD) 
(19). Of note, the TAZ1, RING/PHD and ZZ/TAZ2 domains each forms a 
cysteine/histidine-rich region (CH), named as CH1, CH2 and CH3, respectively. 
BRD, CH2, HAT domain and CH3 form the catalytic core of CBP/p300 (26). 
Other domains and regions are linked to the catalytic core by long stretches of 
unstructured regions (Figure 1A).   
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Figure 1. The regulation of CBP/p300 acetyltransferase activity by AIL, 
RING domain and BRD.  
(A) Schematic representation of human CBP/p300 domain architecture. The 
numbers of amino acid residues of CBP and p300 are labeled. (B) When the 
HAT domain is in its inactive state, the hypoacetylated AIL occupies the 
substrate-binding groove along with the RING domain packed in close proximity 
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to the HAT catalytic site. Upon autoacetylation of the AIL, it is displaced from the 
catalytic site along with the RING domain, making the HAT domain accessible to 
its substrates. (C) The BRD recognizes acetylated histones, preferentially 
acetylated histone H4. Binding of acetylated histone tail by BRD facilitates the 
recruitment of CBP/p300 to chromatin and also increases the access of HAT 
domain to the histone substrate such as the H3 tail. Such an enhancement may 
occur either in cis on the same nucleosome or in trans on adjacent nucleosomes. 
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1.2 Intramolecular regulation mechanisms of CBP/p300 
The functions of CBP/p300, especially their acetyltransferase activity and 
chromatin association, are regulated both intramolecularly by their AIL, BRD, and 
PHD-RING region and intermolecularly by their interacting partners and post-
translational modifications (PTM).   
The AIL (aka autoregulatory loop or activation loop) is a lysine-rich loop 
region adopting a disordered structure within the HAT domain (26, 27) (Figure 
1A). It encompasses amino acid residues (AA) 1520-1581 and 1556-1618 of 
human p300 and CBP, respectively. The AIL was discovered by the Philip Cole 
laboratory when they studied how autoacetylation regulates the HAT activity of 
p300 (28). Up to 17 lysine residues in the AIL and nearby regions of p300 can be 
autoacetylated through an intermolecular mechanism (29, 30). When AIL is 
hypoacetylated, it occupies the catalytic site of HAT domain with its lysine 
residues interacting with the acidic residues in the substrate-binding groove of 
HAT domain. This interaction prevents the positively-charged substrates such as 
lysine-rich histone tails from entering the catalytic site, thus inhibiting the 
acetyltransferase activity of p300 (30, 31). Acetylation on the AIL lysine residues 
disrupts their binding to the substrate-binding groove of HAT domain (30), 
displacing the AIL from the catalytic site. As a result, the catalytic site of HAT 
domain becomes more accessible to its substrates and the acetyltransferase 
activity is thus activated (Figure 1B). In addition to the modulation of HAT activity, 
the AIL also plays a role in regulating CBP/p300 chromatin association. In an in 
vitro system, autoacetylation of the AIL induces the dissociation of p300 from the 
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preinitiation complex (PIC) containing GAL4-VP14 and Mediator at the 
chromatin, which enhances both TFIID binding and transcription initiation (32).  
The CH2 region, located between the BRD and HAT domains, is 
comprised of a RING domain and a PHD. Crystal structure of the p300 catalytic 
core encompassing the BRD, CH2 and HAT domains reveals that CH2 region 
serves as a bridge to connect the BRD and HAT domains (27). The RING 
domain is packed in close proximity to the HAT domain and restricts the access 
of HAT active site to the AIL and other substrates (27, 30). Deletion of the RING 
domain or the mutations in RING that impairs either its structural integrity or its 
interaction with HAT enhances p300 autoacetylation (on K1499) and acetylation 
of p53 substrate (on K382) (27, 30, 33), suggesting RING negatively regulates 
the acetyltransferase activity of p300. Likewise, the RING domain of CBP shows 
a similar regulatory role in both CBP autoacetylation and p53 acetylation (26). 
However, in contrast to the enhanced autoacetylation and p53 acetylation, 
acetylation on histone H3K9 and H3K14 is reduced by the deletion of p300 RING 
domain (33), whereas in the case of CBP, RING deletion has no dramatic effect 
on histone acetylation (26). These results suggest that the regulatory role of 
RING in CBP/p300 acetyltransferase activity may be substrate-specific.  
The PHD of p300 is discontinuous as it is interrupted by the RING domain 
(27). Distinct from the mutations in RING, the mutations either within PHD or at 
PHD-HAT interfaces do not strongly affect p300 autoacetylation or p53 substrate 
acetylation (27). In addition, the PHD is not directly involved in the regulation of 
p300/CBP chromatin binding, because unlike the canonical PHDs that function 
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as readers recognizing modified or unmodified histones (34, 35), the CBP/p300 
PHD does not recognize histones due to the lack of conserved residues critical 
for histone binding (27, 36). To date, the actual function of the PHD in CBP/p300 
remains unknown. 
Acetylated histone lysine can be recognized by specific reader proteins, 
which facilitates the recruitment or retention of transcription co-activators at 
acetylated chromatin loci. BRD is the first discovered reader of histone 
acetylation (Dhalluin et al., 1999). The BRD in CBP/p300 has histone- and 
nucleosome-binding capability (Manning et al., 2001; Ragvin et al., 2004). It 
recognizes multiple acetylated histone peptides in vitro, preferentially di- and tri-
acetylated histone H4 and H2B (27, 36). Substitution of Asn1132 (N1132), a 
conserved residue within the hydrophobic acetyllysine-binding pocket of p300 
BRD, to alanine abolishes its binding to all acetylated histone peptides (27). 
Furthermore, deletion of BRD prevents p300 from forming stable and direct 
interaction with nucleosomes (Manning et al., 2001); and treatment of CBP30, a 
small-molecule inhibitor targeting CBP/p300 BRD, in cells displaces CBP/p300 
from chromatin (37, 38), suggesting that a functional BRD is required for p300-
chromatin association. 
Although CBP/p300 BRD is not adjacent to the HAT domain, it is crucial to 
CBP/p300-mediated histone acetylation. Deletion of BRD greatly impairs the 
ability of p300 to acetylate histones in the contexts of nucleosome (39), native 
chromatin (40) and recombinant chromatin (41) in vitro. In cells, the increase of 
global histone H3K9ac and H3K14ac levels caused by ectopic p300 expression 
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can be diminished by BRD deletion or mutations in its acetyllysine-binding pocket 
(33). Interestingly, in contrast to its critical role in histone substrate acetylation, 
loss of BRD does not significantly affect p300 autoacetylation or the acetylation 
of non-histone substrate such as p53, indicating that BRD is not required for the 
intrinsic acetyltransferase activity of p300 (27, 40, 41). Considering its nature as 
a histone acetylation reader, BRD may function as a “hand” that grabs acetylated 
histone tails, thus increasing the accessibility of nucleosome substrates to the 
catalytic HAT domain of CBP/p300 (Figure 1C). This model is supported by the 
recent finding that preexisting histone H4 acetylation in nucleosomes enhances 
wild-type p300-catalyzed H3K18 acetylation while this enhancement is not 
observed in p300 with BRD deletion or mutations (39). However, it remains 
unclear whether the recognition of acetylated histone H4 by BRD facilitates 
acetylation of the histone H3 within the same nucleosome (in cis model) or in the 
adjacent nucleosomes (in trans model) (Figure 1C). 
The critical role of CBP/p300 BRD in chromatin binding and histone 
acetylation explains the requirement of BRD in CBP/p300-mediated transcription 
enhancement (40) and gene activation (42). Consistently, CBP30 treatment in 
cells, dramatically reduces H3K18ac and H3K27ac level at multiple CBP/p300 
target loci and deactivates transcription of target genes in cells (38, 43). Thus, 
the cooperation between BRD and HAT ensures efficient transcription activation 
by p300/CBP on chromatin.   
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1.3 Intermolecular regulation mechanisms of CBP/p300 
In addition to the intramolecular regulation mechanisms described, 
CBP/p300 are also subject to intermolecular regulation by numerous external 
molecules, which is critical for the functions of CBP/p300 in response to various 
cell signaling pathways (44, 45). Upon the perception of intra- or extracellular 
signals, cells initiate a series of molecular events of signal transduction, leading 
to activation of a group of genes and deactivation of others. CBP/p300 play 
indispensable roles in activating gene expression in response to almost all 
signaling pathways. CBP/p300 receive and execute commands from upstream 
signals through signal-induced protein-protein interactions and PTMs, which 
modulates the dynamics of chromatin association and HAT activity of CBP/p300.  
To date, more than 400 proteins have been reported to interact with 
CBP/p300 (19), including transcription factors, coactivators, mediators and basal 
transcription machinery components. These protein-protein interactions allow 
CBP/p300 to integrate the assembly of transcription activation complexes, to be 
connected with the basal transcription machinery, and to gain access to a subset 
of these proteins for acetylation (19, 46). CBP/p300 contain a number of domains 
that interact with binding partners, including NRID, TAZ1, KIX, TAZ2, IBiD, and to 
a less extent, BRD and HAT domains (46). Notably, a single protein may interact 
with multiple domains or regions of CBP/p300 simultaneously.  
As CBP/p300 do not contain specific DNA-binding domains, recruitment of 
CBP/p300 to specific chromatin regions, such as enhancers or promoters, is 
achieved by interacting with transcription factors that bind to specific DNA 
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sequences. A well-studied example is CREB, a transcription factor that 
recognizes the DNA sequence known as cAMP-response elements (CREs). 
Following the activation of G protein-coupled receptors (GPCRs), accumulated 
cAMP promotes the catalytic subunit of protein kinase A (PKA) to dissociate from 
its regulatory domain, diffuse into nucleus, and phosphorylate the kinase-
inducible domain (KID) of CREB (47). Phosphorylation of KID (at Serine 133) 
greatly increases its binding to the KIX domain of CBP. The CREB-CBP 
interaction mediated by KID-KIX binding thus recruits CBP to CREs, leading to 
the activation of cAMP-responsive genes (7, 48). The hydrogen bond formed 
between phosphorylated Ser133 of CREB KID and Tyr658 of CBP KIX domain 
plays an indispensable role in the interaction between these two domains (49). 
Upon interaction with KIX, the unstructured KID undergoes a coil-to-helix 
transition, forming two helices, with one helix interacting with the hydrophobic 
groove of KIX to stabilize KID-KIX interaction (49).   
Intermolecular protein-protein interactions also directly regulate the HAT 
activity of CBP/p300. P300 was originally discovered as one of the proteins that 
bind E1A, an adenoviral oncoprotein (3, 4). Small E1A protein, the shorter 
isoform of E1A, contains three conserved regions (CR1-3), with CR1 and CR2 
interacting with CBP/p300 and retinoblastoma (RB) proteins, respectively (50). 
Binding of small E1A to the TAZ2 domain of CBP/p300 inhibits their HAT activity 
on histones in vitro, thus repressing CBP/p300-dependent transcription (51-53). 
Infection of cells with adenovirus Type 5 (Ad5) dl1500 that expresses only small 
E1A markedly reduces global H3K18 acetylation level, which mimics the 
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phenotype when both CBP and p300 are depleted (13). Interestingly, small E1A 
can be acetylated at K239 by CBP/p300, implying that as a substrate of 
CBP/p300, small E1A may inhibit HAT activity by directly competing with 
histones for the catalytic site of CBP/p300 (54).  
In contrast to small E1A that inhibits CBP/p300 HAT activity, Mastermind 
like 1 (MAML1), another protein that binds to p300 TAZ2 domain, activates its 
HAT activity both in vitro (55) and in vivo (56), probably through potentiating p300 
autoacetylation (56). MAML1 also helps to recruit p300 to the genomic loci of 
Notch pathway genes (57), suggesting that MAML1 regulates both HAT activity 
and chromatin association of p300. Additionally, dimerization of transcription 
factors that interact with p300 (IRF3, STAT1 etc.) can engage two p300 
molecules, which increases the likelihood of p300 AIL autoacetylation in trans, 
thus enhancing its HAT activity (30).  
In addition to protein interactors, CBP also directly binds to RNAs (58). 
Interestingly, CBP-bound RNAs arise from the chromatin regions with high CBP 
occupancy and a large fraction of them are enhancer RNAs (eRNAs). eRNAs are 
non-coding RNAs transcribed from enhancers (59). Those CBP-bound eRNAs 
directly bind to AIL and displace it from the HAT catalytic site, thus stimulating 
HAT activity in vitro. Consistently, depletion of a certain eRNA in cells greatly 
reduces the H3K18 and H3K27 acetylation level at the same enhancer where 
this eRNA is originated and its associated promoter without affecting CBP 
occupancy (58). This study suggests that when CBP is recruited to active 
enhancers where eRNAs are produced and locally enriched, these eRNAs can 
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bind to the AIL of CBP to stimulate its HAT activity, leading to a local increase of 
CBP-dependent histone acetylation at the same enhancer and associated 
promoters. This finding also indicates that in addition to AIL autoacetylation, cells 
may employ multiple mechanisms to ensure AIL is displaced from the HAT active 
site, safeguarding histone acetylation and gene activation. 
While CBP/p300 catalyze lysine acetylation on histones and non-histone 
proteins, they themselves are also subject to PTMs, such as phosphorylation, 
methylation and SUMOylation, which in turn affects the functionality and 
homeostasis of CBP/p300.  
CBP/p300 can be phosphorylated at various sites. For example, AKT 
phosphorylates p300 at S1834 (60), ERK1/2 phosphorylate p300 at S2279, 
S2315 and S2366 (61), and mTORC1 phosphorylates p300 at S2271, S2279, 
S2291 and S2315 (62). All these phosphorylation events stimulate HAT activity. 
In contrast, PKC-catalyzed p300 phosphorylation at S89 inhibits the catalytic 
activity of p300 (63). The mechanisms by which phosphorylation at the N- or C-
terminal distal regions regulate the HAT domain that is located in the central 
region of p300 have remained elusive. However, Wan et al. recently showed that 
mTORC-catalyzed p300 phosphorylation in the C-terminal region abrogates the 
interaction between p300 HAT and RING domain, thus releasing the HAT 
catalytic site from the RING domain-mediated inhibition (62). This finding 
indicates the existence of crosstalk between inter- and intramolecular regulation 
mechanisms of CBP/p300. Phosphorylation can also regulate CBP/p300 
homeostasis. For instance, phosphorylation of p300 S106 by ATM contributes to 
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p300 stabilization in response to double-strand breaks (DSBs) (64) while 
MAPK/AKT-catalyzed p300 S1834 phosphorylation induces p300 degradation 
during nucleotide excision repair (NER) (65).   
In addition to phosphorylation, other PTMs also contribute to CBP/p300 
regulation. Coactivator-associated arginine methyltransferase 1 (CARM1) 
interacts with and methylates CBP/p300 at multiple arginine residues (66-68). 
Methylation of arginine residues at different regions has distinct regulatory 
outcomes. For example, methylation of the arginine residues within the KIX 
domain of disrupts CBP/p300-CREB interaction, thus reducing the recruitment of 
CBP/p300 to the chromatin of CREB target loci (67) whereas methylation of the 
arginine residues located downstream of KIX increases the recruitment of CBP to 
estrogen receptor (ER)-responsive target genes and enhances CBP HAT activity 
(68, 69). Additionally, SUMOylation of CBP/p300 on the lysine residues upstream 
of BRD negatively regulates CBP/p300-mediated transcription, probably through 
the recruitment of transcriptional corepressor Daxx (70, 71). 
A summary of both intramolecular and intermolecular mechanisms 
regulating p300/CBP is depicted in Figure 2. In the future, a deeper 
understanding of how all the regulatory regions coordinate with each other in the 
context of the complete CBP/p300 proteins will be required.  
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Figure 2. Summary of intramolecular and intermolecular mechanisms 
regulating CBP/p300.  
The mechanisms regulating CBP/p300 acetyltransferase activity (A) and 
chromatin association (B) are shown. Lines with arrows indicate positive 
regulation whereas blunt-ended lines indicate negative regulation. *: the negative 
regulatory role of the RING domain in CBP/p300 acetyltransferase activity is only 
observed on non-histone substrates. 
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1.4 Physiological roles of CBP/p300 
CBP/p300 are essential for various cellular processes such as cell 
proliferation, differentiation and apoptosis (45). They play critical roles in mammal 
development, memory consolidation and pathogenesis.    
Mice homozygous null for either CBP (Crebbp-/-) or p300 (Ep300-/-) are 
embryonic lethal (72-74). Crebbp-/- mice die around embryonic day 10.5~12.5 
(E10.5~E12.5) (72) while Ep300-/- die around E9.0~E11.5 (73). Embryos from 
both mutants display severe defects in growth and neural tube closure (73). In 
addition, Crebbp+/- Ep300+/- double heterozygotes are also embryonic lethal and 
single heterozygotes show reduced viability and multiple developmental defects 
(73, 75, 76). These studies indicate that CBP and p300 exert overlapping 
functions and that there may be a significant dosage requirement for both genes 
during embryonic development.  
Heterozygous mutations/deletions of CREBBP or, less commonly, EP300, 
cause Rubinstein–Taybi syndrome (RTS) (77, 78), a human genetic disorder 
characterized by mental retardation, broad thumbs and toes, craniofacial defects 
and cardiac abnormalities (79). Consistently, monoallelic loss (75, 76) or 
truncation of Crebbp (80) in mice also causes phenotypes reminiscent of RTS.  
In addition, both CBP (75) and p300 (81) are crucial for hematopoiesis. 
However, they seem to play distinct roles in this process. CBP, but not p300, is 
critical to hematopoietic stem cell self-renewal while p300 plays more important 
roles in hematopoietic differentiation (82). Furthermore, CBP is also required for 
long-term memory consolidation in mice brain (83-85). The expression of 
17	
	
deactivated or truncated CBP in mice causes defects in long-term memory 
formation and synaptic plasticity through a dominant-negative mechanism (86). 
CBP/p300 are involved in a number of human cancers. Somatic mutations 
of CREBBP and EP300 frequently occur in multiple types of malignancies (87), 
such as colorectal cancer (88, 89), lung cancer (88, 90), breast cancer (88), skin 
cancer (91) and lymphoma (92-94). Most of these mutations are missense 
mutations clustering within HAT domain or its adjacent regions as well as 
frameshifts and nonsense mutations resulting in protein truncations (Figure 3) 
(92, 93, 95), implying that inactivation of CBP/p300 acetyltransferase activity may 
contribute to tumorigenesis. In addition, CREBBP, and less commonly, EP300, 
are targets of chromosome translocations. MLL-CREBBP (96, 97), MLL-EP300 
(98), MOZ-CREBBP (99) and MOZ-EP300 (100) translocations have been 
implicated in acute myeloid leukemia (AML) and myelodysplastic syndrome. 
The precise roles of CBP/p300 in cancers are complicated. They function 
as tumor suppressors in certain types of cancers, such as colon cancer (101, 
102) and B-cell lymphoma (103). Recently, the elegant work from four labs 
clearly demonstrate the function and mechanism of CBP in B-cell lymphoma 
(103-106). Follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) 
are the two most common types of non-Hodgkin lymphomas derived from 
germinal center (GC) B cells. The mutation rates of CREEBP in DCBCL and FL 
are around 30% and 60%, respectively (92, 93, 107). In comparison, EP300 is 
less frequently mutated in FL and DLBCL. Although GC B cells-specific knockout 
of Crebbp alone is not sufficient to drive oncogenic transformation in mice, it 
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cooperates with Bcl2 overexpression, an event that frequently co-occurs with 
Crebbp mutations in human FL and DLBCL, to promote lymphomagenesis (104, 
106), indicating Crebbp is a tumor suppressor gene. Mechanistically, CBP 
directly binds to the promoter and enhancers of a large number of genes involved 
in B cell signaling and GC exit (104) in GC B cells. Loss of CBP represses the 
expression of these target genes by reducing the histone H3K27 acetylation level 
at their enhancers (103, 104). As most CBP target genes are also occupied by 
the BCL6-containing transcription repressor complex (103, 104), the function of 
this repressor complex may become more dominant on these genes when CBP 
is depleted, which contributes to the silencing of these genes and 
lymphomagenesis (103). Interestingly, the timing of CBP mutation matters in 
lymphoma because loss of Crebbp in early stages of lymphopoiesis is 
advantageous for lymphoid transformation whereas Crebbp loss after lymphoid 
fate commitment does not show an obvious phenotype (105). 
CBP/p300 are also reported to play roles in promoting oncogenesis or 
disease maintenance in other types of cancers. For example, high expression of 
CBP/p300 was correlated with poor prognosis in prostate cancer (108), 
hepatocellular carcinomas (109) and lung cancers (110, 111). In addition, p300 is 
required for androgen receptor (AR) expression and prostate tumorigenesis in a 
PTEN-deficient mouse model (112). CBP/p300 also work as the coactivators of 
AR to support the androgen-induced gene expression in prostate cancer (113). 
Consistently, small-molecule inhibitors targeting the CBP/p300 HAT domain 
efficiently reduces prostate cancer cell viability and represses tumor growth (15, 
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114).  Furthermore, CBP/p300 also facilitate the induction and maintenance of 
AML both in vitro and in vivo (115), which may partially be dependent on their 
interaction with c-Myb (116, 117). The oncogenic roles of CBP/p300 in AML 
suggest that they may be promising therapeutic targets (115, 118). 
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Figure 3. Mutation diagrams of human CREBBP and EP300 genes based on 
215 cancer genomic studies.  
The mutation diagrams of human CREBBP (A) and EP300 (B) genes were 
obtained from cBio Cancer Genomics Portal (http://cbioportal.org) (119, 120) on 
4/27/2018. Mutation types and corresponding color codes are as follows: 
Green: missense mutations. Black: truncating mutations (nonsense, nonstop, 
frameshift deletion or insertion, splice site variant). Brown: in-frame deletion, in-
frame insertion. Purple: all other types of mutations. 
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1.5 ZZ-type zinc finger (ZZ) domain 
The ZZ domain is a small (~45 AA) motif with a cross-braced zinc finger 
topology. It uses s cysteine residues and 2 histidine residues to coordinate 2 Zn2+ 
ions (121). This domain was named ZZ for its capacity to bind two Zn2+ ions 
(122). The ZZ domain was originally identified in dystrophin, a cohesive protein 
critical to muscle fiber integrity, and its related proteins (122). Dystrophin is a vital 
subunit of the dystrophin-associated protein complex that connects the actin 
cytoskeleton of muscle fibers to the surrounding extracellular matrix (123). The 
ZZ domain of dystrophin is located within its C-terminal cysteine-rich domain and 
is required for its interaction with the transmembrane adhesion receptor β-
dystroglycan (124), which is crucial to dystrophin function.  
ZZ domain has been identified in approximately 20 human proteins with 
various functions including chromatin modification, RNA processing, cytoskeletal 
scaffolding, ubiquitin binding or conjugating, and autophagy (121). The 
phylogenetic tree and sequence alignment of the ZZ domains from multiple 
proteins are shown in Figure 4. The function of the ZZ domain has been poorly 
studied. A few ZZ domains were reported to be involved in protein-protein 
interaction. For example, p62 ZZ domain interacts with RIP1 in NF-κB pathway 
(125) and the ZZ domains of the E3 ligase HERC2 (126) and CBP (127) bind 
Small Ubiquitin-like Modifier 1 (SUMO1). However, a more comprehensive 
understanding of ZZ domains’ functions is in need.  
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Figure 4. Phylogenetic tree and sequence alignment of ZZ domains in 
human proteins. 
(A) Phylogenetic tree presentation of ZZ domains in human proteins. (B) 
Sequence alignment of human ZZ domains. Identical residues are in white text 
shaded in red. Conserved residues are in red text and framed by blue line. 
Figure 4 is adapted from Mi W, Zhang Y, Lyu J, Wang X, Tong Q, Peng D, Xue 
Y, Tencer AH, Wen H, Li W, Kutateladze TG and Shi X. 2018. The ZZ-type zinc 
finger of ZZZ3 modulates the ATAC complex-mediated histone acetylation and 
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gene activation. Nat Comm. 9:3759. Permission to reuse these figures for thesis 
was obtained from www.copyright.com with license number 4456700921676. 
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1.6 Small cell lung cancer (SCLC) 
Lung cancer is divided into three main subtypes (Figure 5A): non-small 
cell lung cancer (NSCLC), small cell lung cancer (SCLC) and lung carcinoid 
tumor (http://www.cancer.org/cancer/lungcancer/index). SCLC, the most 
aggressive subtype, accounts for 10~15% of all lung cancer cases and is tightly 
associated with heavy smoking behavior in patients (128). This disease is 
characterized by rapid tumor expansion, frequent relapse and early metastasis 
(129). SCLC cells are small, poorly differentiated, and likely originated from 
neuroendocrine cells within the pulmonary epithelium (130, 131).  
SCLC is commonly divided into limited stage and extensive stage. Limited 
stage SCLC is confined to a single radiation field in one side of the chest while 
extensive stage SCLC has distant metastases (132). Approximately two-thirds of 
SCLC patients are diagnosed with extensive stage (133). In general, limited-
stage patients are treated concurrently with chemotherapy in combination with 
radiation therapy, whereas extensive-stage patients are treated with 
chemotherapy alone (134). Despite the initial good response to frontline 
therapies in most SCLC patients, the disease will soon relapse with resistance to 
second-line and subsequent therapies. Numerous clinical trials since the 1970s 
have failed and there are still no approved targeted drugs for this disease. The 5-
year survival rate of SCLC patients remains lower than 7% (128, 134). 
The mutation rate of SCLC is among the highest, which can be explained 
by its link to tobacco exposure (135). Genomic studies have revealed multiple 
recurrent genetic alterations in SCLC (Figure 5B, C). For example, loss-of-
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function mutations in TP53 and RB1 are present in almost all SCLC samples (95, 
136, 137). Amplified SOX2 (137) and MYC family genes (138, 139), activated 
phosphatidylinositol 3 kinase (PI3K) pathway and inactivated NOTCH signaling 
pathway are also common (95, 136, 140, 141).  
In addition to the genetic alterations, dysregulated epigenetic mechanisms 
also contribute to SCLC onset and progression. For example, Enhancer of zeste 
homolog 2 (EZH2), a core subunit of the polycomb repressive complex 2 (PRC2) 
and a histone H3K27-specific methyltransferase, is highly expressed in SCLC 
compared to normal lung tissues and other cancer types (142-145). This might 
be the result of E2 promoter binding factors (E2Fs) upregulation, which is caused 
by the universal RB1 loss or frequent E2Fs amplification in SCLC (143). 
Overexpressed EZH2 directly silences TGFBR2, the gene encoding transforming 
growth factor-β (TGF-β) type II receptor (TβRII), by catalyzing histone H3K27 
trimethylation at its promoter, which suppresses TGF-β pathway, enabling SCLC 
cells to escape apoptosis (146). EZH2 also directly silences Schlafen family 
member 11 (SLFN11), a gene critical to DNA damage response, to promote the 
resistance to chemotherapy in SCLC (147). Inhibiting EZH2 with small molecules 
such as EPZ reduces SCLC xenograft tumor growth (145) and prevents the 
acquisition of chemoresistance in SCLC (147).  
While anti-tumor genes are silenced, oncogenes such as MYC, MYCN, 
NFIB, SOX2, NEUROD1 and ASCL1, are expressed at very high levels in SCLC 
(148-153). Recently it has been reported that these highly-expressed oncogenes 
are associated with large and clustered enhancer elements containing 
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extraordinarily high level of H3K27ac (153, 154), namely super-enhancers (155). 
Many factors involved in transcription activation, such as BET proteins, mediator 
components and p300/CBP, are enriched at super-enhancers to maintain the 
activation of those oncogenes (154). Inhibition of the BET family member BRD4 
by JQ1 (156, 157) or the cyclin-dependent kinase CDK7 by THZ1 (153) in SCLC 
suppresses the expression of super-enhancer-associated oncogenes and cell 
growth. 
EP300 and CREBBP are also frequently mutated in SCLC (90, 95, 136, 
137, 158) with mutation frequencies of 13% and 15%, respectively (136). 
Alterations in EP300 and CREBBP are mutually exclusive (95). Except for the 
inactivating translocations, mutations of EP300 and CREBBP are clustered within 
the HAT domain and its adjacent regions (95, 136). However, only a few of 
mutations in HAT domain have been confirmed to reduce HAT activity (95), 
whereas the functional consequences of most mutations are still elusive. SCLC 
patient survival analysis has not revealed any significant differences between 
individuals with and without EP300/CREBBP mutations (136). Interestingly, high 
p300/CBP expression levels have been reported to be associated with poor 
overall survival for resected SCLC patients (111). Direct evidence clearly 
revealing the roles of p300/CBP in SCLC initiation and progression is still lacking.  
The pathogenesis of SCLC is a complex, multi-step process. 
Understanding the genetic and epigenetic basis of SCLC will contribute to the 
development of novel therapies. In the future, more multidisciplinary and 
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comprehensive studies will be required for translating these biological findings 
into clinical practice.  
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Figure 5. Genetic alterations in small cell lung cancer.  
(A) The classification of lung cancers. (B) The somatic mutations of candidate 
genes in SCLC tumor samples. Tumor samples are arranged from left to right. 
Alterations of SCLC candidate genes are annotated for each sample according to 
the color panel below the image. The somatic mutation frequencies for each 
candidate gene are plotted on the right panel. Mutation rates and type of base-
pair substitution are displayed in the top and bottom panel, respectively. 
Significant candidate genes are highlighted in bold (*corrected q-values < 0.05, 
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†P < 0.05, ‡P < 0.01). The respective level of significance is displayed as a 
heatmap on the right panel. Genes that are also mutated in murine SCLC tumors 
are denoted with a § symbol. Mutated cancer census genes of therapeutic 
relevance are denoted with a + symbol. (C) Somatic copy number alterations 
determined for 142 human SCLC tumors by single nucleotide polymorphism 
(SNP) arrays. Significant amplifications (red) and deletions (blue) were 
determined for the chromosomal regions and are plotted as q-values 
(significance < 0.05). 
Figure 5B and 5C are adapted from George, J., J. S. Lim, S. J. Jang, Y. Cun, L. 
Ozretic, G. Kong, F. Leenders, X. Lu, L. Fernandez-Cuesta, G. Bosco, C. Muller, 
I. Dahmen, N. S. Jahchan, K. S. Park, D. Yang, A. N. Karnezis, D. Vaka, A. 
Torres, M. S. Wang, J. O. Korbel, R. Menon, S. M. Chun, D. Kim, M. Wilkerson, 
N. Hayes, D. Engelmann, B. Putzer, M. Bos, S. Michels, I. Vlasic, D. Seidel, B. 
Pinther, P. Schaub, C. Becker, J. Altmuller, J. Yokota, T. Kohno, R. Iwakawa, K. 
Tsuta, M. Noguchi, T. Muley, H. Hoffmann, P. A. Schnabel, I. Petersen, Y. Chen, 
A. Soltermann, V. Tischler, C. M. Choi, Y. H. Kim, P. P. Massion, Y. Zou, D. 
Jovanovic, M. Kontic, G. M. Wright, P. A. Russell, B. Solomon, I. Koch, M. 
Lindner, L. A. Muscarella, A. la Torre, J. K. Field, M. Jakopovic, J. Knezevic, E. 
Castanos-Velez, L. Roz, U. Pastorino, O. T. Brustugun, M. Lund-Iversen, E. 
Thunnissen, J. Kohler, M. Schuler, J. Botling, M. Sandelin, M. Sanchez-
Cespedes, H. B. Salvesen, V. Achter, U. Lang, M. Bogus, P. M. Schneider, T. 
Zander, S. Ansen, M. Hallek, J. Wolf, M. Vingron, Y. Yatabe, W. D. Travis, P. 
Nurnberg, C. Reinhardt, S. Perner, L. Heukamp, R. Buttner, S. A. Haas, E. 
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Brambilla, M. Peifer, J. Sage, and R. K. Thomas. 2015. Comprehensive genomic 
profiles of small cell lung cancer. Nature 524: 47-53. Permission to reuse these 
figures for thesis was obtained from www.copyright.com with license number: 
4324930807544. 
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Chapter 2. Materials and Methods 
 
2.1 Plasmids and molecular cloning. 
The coding DNA sequences (CDS) encoding human full-length p300 
protein and various p300 fragments were amplified from pcDNA3.1-p300 vector 
(#23252) purchased from Addgene. The CDS of full-length p300 and p300 BD-
RING-PHD-HAT-ZZ-TAZ2 region (BRPHZ, amino acids 1035-1830) and cloned 
into pENTR3C vector and subsequently cloned into p3FLAG and pCDH-3FLAG 
destination vectors using Gateway techniques (Invitrogen). The CDS encoding 
the human p300 BD-RING-PHD-HAT-ZZ region (BRPHZ, amino acids 1035-
1720) and ZZ domain (amino acids 1650-1720) were cloned into the pGEX-6P-1 
vector (GE Healthcare). Point mutations and deletions were generated using a 
site-directed mutagenesis kit (Stratagene) and verified by Sanger sequencing.  
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) 
guide RNAs (gRNAs) were designed by the online CRISPR design tool of Feng 
Zhang’s lab (http://crispr.mit.edu/) for human and mouse EP300/CREBBP genes. 
Two gRNAs targeting the 5’ region of each gene’s CDS and one non-target 
control gRNA were used in this study. The oligos encoding those gRNAs were 
annealed and then cloned into lentiCRISPRv2 puro vector (#98290, Figure 6) 
purchased from Addgene. 
The detailed information of all the vectors and oligos are included in Table 
1 and 2, respectively.  
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Figure 6. The map of LentiCRISPR v2 Puro vector.  
The vector was linearized by BsmI digestion. The DNAs encoding gRNAs were 
inserted between two BsmI restriction sites. This figure is made using DNASTAR 
SeqBuilder Pro.  
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Name Region cloned Application 
pGEX-p300-ZZ p300 AA1650-1720 Prokaryotic expression 
pGEX-p300-ZZ D1664A p300 AA1650-1720 Prokaryotic expression 
pGEX-p300-ZZ F1666A p300 AA1650-1720 Prokaryotic expression 
pGEX-p300-ZZ Y1668A p300 AA1650-1720 Prokaryotic expression 
pGEX-p300-ZZ N1671A p300 AA1650-1720 Prokaryotic expression 
pGEX-p300-ZZ R1680C p300 AA1650-1720 Prokaryotic expression 
pGEX-p300-ZZ W1681A p300 AA1650-1720 Prokaryotic expression 
pGEX-p300-ZZ D1688K p300 AA1650-1720 Prokaryotic expression 
pGEX-p300-ZZ D1690A p300 AA1650-1720 Prokaryotic expression 
pGEX-p300-BRPHZ p300 AA1035-1720 Prokaryotic expression 
pGEX-p300-BRPHZ ∆AIL p300 AA1035-1720 (1520-1581 del) Prokaryotic expression 
pGEX-p300-BRPH p300 AA1035-1669 Prokaryotic expression 
pGEX-p300-BRPHZ N1132A p300 AA1035-1720 Prokaryotic expression 
pGEX-p300-BRPHZ D1399A p300 AA1035-1720 Prokaryotic expression 
pGEX-p300-BRPHZ N1671A p300 AA1035-1720 Prokaryotic expression 
pGEX-p300-BRPHZ D1690A p300 AA1035-1720 Prokaryotic expression 
pGEX-p300-BRPHZ N1132A 
D1690A p300 AA1035-1720 Prokaryotic expression 
pENTR3C-p300-BRPHZT p300 AA1035-1830 Gateway cloning 
pENTR3C-p300-BRPHZT ∆ZZ p300 AA1035-1830 (1664-1705 del) Gateway cloning 
pENTR3C-p300-BRPHZT ∆BRD p300 AA1162-1830 Gateway cloning 
pENTR3C-p300-BRPHZT 
∆ZZ&BRD 
p300 AA1162-1830 
(1664-1705 del) Gateway cloning 
pENTR3C-p300-BRPHZT ∆AIL p300 AA1035-1830 (1520-1581 del) Gateway cloning 
pENTR3C-p300-BRPHZT N1132A p300 AA1035-1830 Gateway cloning 
pENTR3C-p300-BRPHZT D1399A p300 AA1035-1830 Gateway cloning 
pENTR3C-p300-BRPHZT N1671A p300 AA1035-1830 Gateway cloning 
pENTR3C-p300-BRPHZT D1690A p300 AA1035-1830 Gateway cloning 
pENTR3C-p300-BRPHZT N1132A 
D1690A p300 AA1035-1830 Gateway cloning 
pENTR3C-p300FL p300 full-length CDS Gateway cloning 
pENTR3C-p300FL N1671A p300 full-length CDS Gateway cloning 
pENTR3C-p300FL D1690A p300 full-length CDS Gateway cloning 
 
Table 1. Plasmids used in this study. 
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Name Region cloned Application 
pCDH-3FLAG-p300-BRPHZT p300 AA1035-1830 Lentiviral expression 
pCDH-3FLAG-p300-BRPHZT ∆ZZ p300 AA1035-1830 (1664-1705 del) Lentiviral expression 
pCDH-3FLAG-p300-BRPHZT ∆BRD p300 AA1162-1830 Lentiviral expression 
pCDH-3FLAG-p300-BRPHZT 
∆ZZ&BRD 
p300 AA1162-1830 
(1664-1705 del) Lentiviral expression 
pCDH-3FLAG-p300-BRPHZT ∆AIL p300 AA1035-1830 (1520-1581 del) Lentiviral expression 
pCDH-3FLAG-p300-BRPHZT N1132A p300 AA1035-1830 Lentiviral expression 
pCDH-3FLAG-p300-BRPHZT D1399A p300 AA1035-1830 Lentiviral expression 
pCDH-3FLAG-p300-BRPHZT N1671A p300 AA1035-1830 Lentiviral expression 
pCDH-3FLAG-p300-BRPHZT D1690A p300 AA1035-1830 Lentiviral expression 
pCDH-3FLAG-p300-BRPHZT N1132A 
D1690A p300 AA1035-1830 Lentiviral expression 
pCDH-3FLAG-p300FL p300 full-length CDS Lentiviral expression 
pCDH-3FLAG-p300FL N1671A p300 full-length CDS Lentiviral expression 
pCDH-3FLAG-p300FL D1690A p300 full-length CDS Lentiviral expression 
p3FLAG-p300FL p300 full-length CDS Transfection 
p3FLAG-p300FL N1671A p300 full-length CDS Transfection 
p3FLAG-p300FL D1690A p300 full-length CDS Transfection 
Human CBP gRNA5-LentiCRISPRv2 NA Gene depletion 
Human CBP gRNA6-LentiCRISPRv2 NA Gene depletion 
Human p300 gRNA1-LentiCRISPRv2 NA Gene depletion 
Human p300 gRNA6-LentiCRISPRv2 NA Gene depletion 
Mouse CBP gRNA3-LentiCRISPRv2 NA Gene depletion 
Mouse CBP gRNA6-LentiCRISPRv2 NA Gene depletion 
Mouse p300 gRNA2-LentiCRISPRv2 NA Gene depletion 
Mouse p300 gRNA5-LentiCRISPRv2 NA Gene depletion 
 
Table 1 (continue). Plasmids used in this study. 
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2.2 Primers 
The sequences and usages of all primers/oligos used in this study are 
described in Table 2. 
Oligo name Sequence (5'-3') Application 
p300-fl-KpnI-F GGGGTACCATGGCCGAGAATGTG Cloning 
p300-fl-XhoI-R GCGCCTCGAGCTAGTGTATGTCTAG Cloning 
p300-BRD-EcoRI-F  CGGAATTCACCCAGTCATCTCC Cloning 
p300-PHD-EcoRI-F  CGGAATTCTACTGTTGTGGCAGA Cloning 
p300-HAT-XhoI-R  GCGCCTCGAGTTAGGTGTAGACAAAGCG Cloning 
p300-ZZ-XhoI-R  GCGCCTCGAGTTACTGCTGGTTGTTGC Cloning 
p300-TAZ2-XhoI-R  GCGCCTCGAGTTACCTGCGAAGCATTTG Cloning 
p300-dAIL-F  GAAAGCATTAAGGAACAGAAACTATATGCC Deletion 
p300-dAIL-R GGCATATAGTTTCTGTTCCTTAATGCTTTC Deletion 
p300-dZZ-F  CACACGCAGAGCCAGGAGAAACTAGGCCTT Deletion 
p300-dZZ-R AAGGCCTAGTTTCTCCTGGCTCTGCGTGTG Deletion 
p300-ZZ-D1664A-F CACACGCAGAGCCAGGCCCGCTTTGTCTACACC Mutagenesis 
p300-ZZ-D1664A-R GGTGTAGACAAAGCGGGCCTGGCTCTGCGTGTG Mutagenesis 
p300-ZZ-F1666A-F CAGAGCCAGGACCGCGCTGTCTACACCTGCAAT Mutagenesis 
p300-ZZ-F1666A-R ATTGCAGGTGTAGACAGCGCGGTCCTGGCTCTG Mutagenesis 
p300-ZZ-Y1668A-F CAGGACCGCTTTGTCGCCACCTGCAATGAATGC Mutagenesis 
p300-ZZ-Y1668A-R GCATTCATTGCAGGTGGCGACAAAGCGGTCCTG Mutagenesis 
p300-ZZ-N1671A-F TTTGTCTACACCTGCGCTGAATGCAAGCACCAT Mutagenesis 
p300-ZZ-N1671A-R ATGGTGCTTGCATTCAGCGCAGGTGTAGACAAA Mutagenesis 
p300-ZZ-R1680C-F CACCATGTGGAGACATGCTGGCACTGTACTGTC Mutagenesis 
p300-ZZ-R1680C-R GACAGTACAGTGCCAGCATGTCTCCACATGGTG Mutagenesis 
p300-ZZ-W1681A-F CATGTGGAGACACGCGCGCACTGTACTGTCTGT Mutagenesis 
p300-ZZ-W1681A-R ACAGACAGTACAGTGCGCGCGTGTCTCCACATG Mutagenesis 
p300-ZZ-D1688K-F TGTACTGTCTGTGAGAAGTATGACTTGTGTATC Mutagenesis 
p300-ZZ-D1688K-R GATACACAAGTCATACTTCTCACAGACAGTACA Mutagenesis 
p300-ZZ-D1690A-F GTCTGTGAGGATTATGCCTTGTGTATCACCTGC Mutagenesis 
p300-ZZ-D1690A-R GCAGGTGATACACAAGGCATAATCCTCACAGAC Mutagenesis 
p300-HAT-D1399A-F TACATATCTTACCTCGCTAGTGTTCATTTCTTC Mutagenesis 
p300-HAT-D1399A-R GAAGAAATGAACACTAGCGAGGTAAGATATGTA Mutagenesis 
p300-BRD-N1132A-F AATGCCTGGTTATATGCCCGGAAAACATCACGG Mutagenesis 
p300-BRD-N1132A-R CCGTGATGTTTTCCGGGCATATAACCAGGCATT Mutagenesis 
 
Table 2. Oligos used in this study. 
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Oligo name Sequence (5'-3') Application 
NBPF1-46k-F TCAAGAGCCCAGCCAACAC ChIP-qPCR 
NBPF1-46k-R CAGCCCTACAGAAGTGCCTTTT ChIP-qPCR 
NOTCH2NL-d4k-F AGCCCTTCGGGACACATG ChIP-qPCR 
NOTCH2NL-d4k-R GGGCTTCCACTCTTCCAAAGT ChIP-qPCR 
DMPK-1k-F CACCCAGAAGAACCCAAAGTTG ChIP-qPCR 
DMPK-1k-R GGAGAACCAGCTTTGCAGACA ChIP-qPCR 
PDE4DIP-U10k-F TCTCGTGCCATCCACTCTATCTC ChIP-qPCR 
PDE4DIP-U10k-R GCCTGGATGTGCTGGACAA ChIP-qPCR 
INSM1-D8k-F CCCAGTTGTTGCCCCAGTAA ChIP-qPCR 
INSM1-D8k-R TGGTGCCCAAGCCATCA ChIP-qPCR 
ASCL1-P-F GCACGCACTGCAACAACAA ChIP-qPCR 
ASCL1-P-R CTCCCGCTCCTTGCAAACT ChIP-qPCR 
ASCL1-D5k-F GAGTTTGAGACTAGCCTGGGAAAG ChIP-qPCR 
ASCL1-D5k-R CCAGCACCTTCAGCTAATTTTTG ChIP-qPCR 
Myc-ChIP-P1k-F CAGCCCGAGACTGTTGCA ChIP-qPCR 
Myc-ChIP-P1k-R TTTCAGAAGAGACAAATCCCCTTT ChIP-qPCR 
Myc-ChIP-P0.1k-F CCCGGGTTCCCAAAGC ChIP-qPCR 
Myc-ChIP-P0.1k-R CCAGACCCTCGCATTATAAAGG ChIP-qPCR 
mMyc-RTq-F GTCTTTCCCTACCCGCTCAAC RT-qPCR 
mMyc-RTq-R GTGGAATCGGACGAGGTACAG RT-qPCR 
mMycl-RTq-F GGCAACAGCAACTGCAAAAG RT-qPCR 
mMycl-RTq-R CAGGCGTTCTGGTCGGTTAG RT-qPCR 
mMycn-RTq-F TGCCCGCGAGAAGCTAGA RT-qPCR 
mMycn-RTq-R CGTGGCCGTGCTGTAGTTT RT-qPCR 
mAscl1-RTq-F TCCTGTCGCCCACCATCT RT-qPCR 
mAscl1-RTq-R AGAACCCGCCATAGAGTTCAAG RT-qPCR 
mNfib-RTq-F CCCGTGCTGTGTCTTATCCA RT-qPCR 
mNfib-RTq-R AGGCAGTCGATCCTCCTAATCTT RT-qPCR 
MYC-RTq-F CGTCTCCACACATCAGCACAA RT-qPCR 
MYC-RTq-R CACTGTCCAACTTGACCCTCTTG RT-qPCR 
MYCL1-RTq-F GGAGCGGACATGGACTACGA RT-qPCR 
MYCL1-RTq-R GCCGTGGAGCGGTAGAAAT RT-qPCR 
MYCN-RTq-F AATTGAACACGCTCGGACTTG RT-qPCR 
MYCN-RTq-R AATGTGCAAAGTGGCAGTGACT RT-qPCR 
ASCL1-RTq-F GAGCAACTGGGACCTGAGTCA RT-qPCR 
ASCL1-RTq-R CCCACTGCTTTTGCACACAA RT-qPCR 
NEUROD1-RTq-F AAGGTGGTGCCTTGCTATTCTAA RT-qPCR 
NEUROD1-RTq-R CCAAGCGCAGAGTCTCGATT RT-qPCR 
 
Table 2 (continue). Oligos used in this study. 
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Oligo name Sequence (5'-3') Application 
CBP-gRNA5-5' CACCGCGCGGGACTGAACACCGCAC CRISPR gRNA 
CBP-gRNA5-3' AAACGTGCGGTGTTCAGTCCCGCGC CRISPR gRNA 
CBP-gRNA6-5' CACCGGCAGCCGAACAGTGCTAACA CRISPR gRNA 
CBP-gRNA6-3' AAACTGTTAGCACTGTTCGGCTGCC CRISPR gRNA 
EP300-gRNA1-5' CACCGGTTCAATTGGAGCAGGCCGA CRISPR gRNA 
EP300-gRNA1-3' AAACTCGGCCTGCTCCAATTGAACC CRISPR gRNA 
EP300-gRNA6-5' CACCGGAATTGGGACTAACCAATGG CRISPR gRNA 
EP300-gRNA6-3' AAACCCATTGGTTAGTCCCAATTCC CRISPR gRNA 
mCBP-gRNA3-5' CACCGGGCCTTCTCAATAGTAACTC CRISPR gRNA 
mCBP-gRNA3-3' AAACGAGTTACTATTGAGAAGGCCC CRISPR gRNA 
mCBP-gRNA6-5' CACCGAGCGGCTCTAGCATCAACCC CRISPR gRNA 
mCBP-gRNA6-3' AAACGGGTTGATGCTAGAGCCGCTC CRISPR gRNA 
mEP300-gRNA2-5' CACCGATGAACGGTTCCATTGGAGC CRISPR gRNA 
mEP300-gRNA2-3' AAACGCTCCAATGGAACCGTTCATC CRISPR gRNA 
mEP300-gRNA5-5' CACCGGGCCACCGACTCCCATGTTG CRISPR gRNA 
mEP300-gRNA5-3' AAACCAACATGGGAGTCGGTGGCCC CRISPR gRNA 
NT-gRNA2-5' CACCGGGATACTTCTTCGAACGTTT CRISPR gRNA 
NT-gRNA2-3' AAACAAACGTTCGAAGAAGTATCCC CRISPR gRNA 
 
Table 2 (continue). Oligos used in this study. 
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2.3 Antibodies 
The information of all the primary and secondary antibodies used in this 
study is included in Table 3. 
 
Antibody Vendor Catalog # Application 
Anti-H3 Abcam Ab1791 WB, ChIP 
Anti-H3K4ac Abcam Ab176799 WB 
Anti-H3K9ac Abcam Ab32129 WB 
Anti-H3K9ac Active Motif 61251 WB 
Anti-H3K18ac Active Motif 39755 WB, ChIP 
Anti-H3K27ac Abcam Ab4729 WB, ChIP 
Anti-acetyl-Histone H4  Millipore 06-598 WB 
Anti-GST Santa Cruz Sc-459 WB 
Anti-FLAG  Sigma F1804 WB, ChIP 
Anti-p300 Santa Cruz Sc-585 WB 
Anti-CBP Santa Cruz Sc-369 WB 
Anti-β-Tubulin Sigma T8328 WB 
IRDye® 800CW Goat 
anti-Rabbit IgG LI-COR 926-32211 WB (secondary) 
IRDye® 680LT Goat anti-
Mouse IgG LI-COR 926-68020 WB (secondary) 
Peroxidase-conjugated 
Donkey anti-Mouse IgG 
Jackson Immuno 
Research 715-035-150 WB (secondary) 
Peroxidase-conjugated 
Donkey anti-Rabbit IgG 
Jackson Immuno 
Research 711-035-152 WB (secondary) 
  
Table 3. Antibodies used in this study.  
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2.4 Cell lines 
The information of all cell lines used was described in Table 4. They were 
mycoplasma-negative and tested for authentication by short tandem repeat 
(STR) profiling by the MDACC Characterized Cell Line Core. 
Cell line Species Cancer type Medium Source 
HEK293T Human Kidney cancer DMEM* ATCC 
HBEC Human Lung epithelial control cell KSFM** Dr. John Heymach 
A549 Human NSCLC RPMI Dr. John Heymach 
H1299 Human NSCLC RPMI Dr. John Heymach 
H1048 Human SCLC HITES*** Dr. Lauren Byers 
H1836 Human SCLC HITES Dr. Lauren Byers 
H209 Human SCLC RPMI**** Dr. Lauren Byers 
H2171 Human SCLC HITES Dr. Lauren Byers 
H524 Human SCLC RPMI Dr. Lauren Byers 
H69 Human SCLC RPMI Dr. Lauren Byers 
H82 Human SCLC RPMI Dr. Lauren Byers 
ID43 Mouse Pre-SCLC RPMI Dr. Kwon-Sik Park 
Kp1 Mouse SCLC RPMI Dr. Julien Sage 
Kp3 Mouse SCLC RPMI Dr. Julien Sage 
Kp3+GFP+Luc Mouse SCLC RPMI Dr. Julien Sage 
Kp12 Mouse SCLC RPMI Dr. Julien Sage 
259-2 Mouse SCLC RPMI Dr. Julien Sage 
 
Table 4. Cell lines used in this study. 
*DMEM: Dulbecco's Modified Eagle Medium	(Cellgro) supplemented with 10% 
fetal bovine serum (FBS) (Sigma). **KSFM:	Keratinocyte serum-free medium. 
***HITES: DMEM/F12 Medium (Cellgro) supplemented with ITS mixture (Lonza, 
containing 0.005 mg/ml Insulin, 0.01 mg/ml Transferrin and 30nM Sodium 
selenite), 10 nM Hydrocortisone (Sigma), 10 nM β-estradiol (Sigma), 4.5 mM L-
glutamine (Cellgro) and 5% FBS (Sigma). **** RPMI: Roswell Park Memorial 
Institute 1640 medium (Cellgro) supplemented with 10% FBS (Sigma). 
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2.5 Protein expression and purification 
The CDS of p300BRPHZ or p300ZZ cloned in the pGEX-6P-1 vector were 
expressed in BL21 Rosetta 2 cells. Protein production was induced with 0.2 mM 
IPTG and cultured overnight at 16 °C in Luria broth (LB) medium supplemented 
with 0.05 mM ZnCl2. The glutathione S-transferase (GST)-tagged proteins were 
purified on glutathione Sepharose 4B beads (Amersham) in binding buffer (50 
mM Tris-HCl pH 7.5, 150 mM NaCl, 0.05% NP-40, 1 mM PMSF plus protease 
inhibitors (Roche)) at 4 °C for 4 hours and eluted by 100 mM Tris pH 8.0 
containing 15 mg/mL Reduced Glutathione (Sigma) at 4 °C for overnight. Eluted 
proteins were supplemented with 25% glycerol before frozen at -80 °C. All 
proteins harboring mutations or deletions were expressed and purified as WT 
proteins.  
 
2.6 Peptide microarray and pull-down assays 
 Biotinylated histone peptides bearing different modifications were 
synthesized at CPC, LLC. For peptide microarray, biotinylated histone peptides 
were printed in triplicate onto a streptavidin-coated slide (PolyAn) using a 
VersArray Compact Microarrayer (Bio-Rad). After a short blocking with biotin 
(Sigma), the slides were incubated with the glutathione S-transferase (GST)-
tagged p300 ZZ domain in binding buffer (50 mM Tris-HCl, pH 7.5, 250 mM 
NaCl, 0.1% NP-40, 1 mM PMSF, 20% FBS) overnight at 4 °C with gentle shake. 
After washed with the same buffer, the slides were probed with an anti-GST 
primary antibody and then a fluorescein-conjugated secondary antibody and 
41	
	
visualized using a GenePix 4000 scanner (Molecular Devices). For peptide pull-
down, 1 μg of each biotinylated histone peptide was incubated with 1-2 μg of 
GST-fused p300 ZZ domain in binding buffer (50 mM Tris-HCl pH 7.5, 250 mM 
NaCl, 0.1% NP-40, 1 mM PMSF) for overnight with rotation at 4 °C. Streptavidin 
beads (Amersham) were added to the mixture, and the mixture was incubated for 
1 hour with rotation at 4 °C. The beads were then washed three times and the 
bound proteins were analyzed using SDS–PAGE and Western blotting. 
 
2.7 Calf thymus histone pull-down assay 
2 µg GST-tagged p300ZZ domain were incubated with 10 µg of calf thymus 
total histones (Worthington) in binding buffer (50 mM Tris-HCl pH 7.5, 1M NaCl, 
1% NP-40) at 4 °C for overnight with rotation. Glutathione Sepharose 4B beads 
(Amersham) were added to the solution and incubate for 1 h. The beads were 
then washed six times using binding buffer and the bound histones were 
detected using SDS–PAGE and Western blotting. 
 
2.8 In vitro histone acetyltransferase (HAT) assays 
 For HAT assays on recombinant nucleosomes containing full-length histone 
H3.1, purified wild type or mutated p300BRPHZ (300 nM) was incubated with 
recombinant mononucleosome (100 nM) in HAT reaction buffer (50 mM Tris 
pH 8.0, 0.1 mM EDTA, 10% glycerol, 1 mM PMSF and 1mM DTT) in a total 
volume of 50 µL. After pre-warming at 37 °C for 5 minutes, reactions were 
initiated with the addition of acetyl-CoA (Sigma) to a final concentration of 0.1 
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mM and incubated for 10~80 minutes at 37 °C. For assays comparing the HAT 
activities on recombinant nucleosomes containing full-length histone H3.1 and N-
terminally truncated H3.1, wild type p300BRPHZ fragment (50 nM) and 
monobucleosome (500 nM) were incubated under the same condition for 1 to 6 
hours. Reactions were quenched by flash-freezing in liquid nitrogen and then 
analyzed by SDS-PAGE and Western blot analysis. Western blot results were 
quantified by LI-COR Odyssey and normalized to a common standard sample.  
 
2.9 Western blot 
 Cells were lysed in RIPA buffer (50 mM TrisHCl pH7.4, 150 mM NaCl, 2 
mM EDTA, 1% NP-40, 0.1% SDS) and sonicated for 20s at 15% intensity. 
Generally, 15~30 µg protein lysate was loaded into various percentages of SDS-
polyacrylamide gels for electrophoresis in PAGE running buffer (25 mM Tris, 192 
mM glycine, 0.1% SDS, pH8.3). Then proteins were transferred to 0.2 or 0.45 μm 
PVDF membrane in transfer buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, 
20% methanol). The membranes were blocked by TBST buffer (150 mM NaCl, 
10 mM Tris pH8.0, 0.1% Tween20) supplemented with 5% non-fat milk for 1 hour 
at room temperature and then blotted with primary antibodies overnight at 4°C on 
an orbital shaker. After three times of wash by TBST, membranes were 
incubated with secondary antibodies for 1 hour at room temperature and washed 
again by TBST for 3 times. The membranes were then either used for film-
developing in darkroom after incubating with ECL Western Blotting Detection 
Reagent (GE Healthcare) for 5 min or directly scanned by LI-COR Odyssey. 
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2.10 Transfection and lentiviral infection 
Transient transfection was performed using X-tremeGENE DNA 
transfection reagent (Roche). 48 h after transfection, cells were collected for 
Western blot analysis. For packaging lentivirus, 293T cells were co-transfected 
with pMD2.G, pPAX2 (Addgene) and pCDH (or LentiCRISPRv2) constructs using 
X-tremeGENE DNA transfection reagent (Roche). For infections, cells were 
incubated with viral supernatants in the presence of 8 mg/ml polybrene; after 48 
hours, the infected cells were selected with blasticidin (10 µg/ml) or puromycin (2 
µg/ml) for 4-6 days before experiments. 
  
2.11 Salt fractionation 
The method of salt fractionation was modified from Tjian lab protocol (159). In 
short, cells were swollen with hypotonic buffer (10 mM HEPES pH 7.9, 1.5 mM 
MgCl2, 10mM KCl) and lysed by gentle disruption to isolate nuclei. The nuclei 
were incubated with wash buffer (20 mM HEPES pH 7.9, 1.5 mM MgCl2, 0.2mM 
EDTA, 25% glycerol) containing 75 mM NaCl for 30 min at 4 °C and then pelleted 
and the supernatant fraction was collected. The nuclei were then similarly 
washed by wash buffer containing 150mM, 300mM and 600mM NaCl and the 
supernatant fraction of each step was collected (Figure 7). After the final wash 
step, the pellet was resuspended and sonicated before collection. All fractions 
collected were analyzed by SDS–PAGE and Western blotting. 
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Figure 7. The workflow for salt fractionation assay.  
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2.12 Chromatin immunoprecipitation (ChIP) and ChIP-seq 
ChIP analysis was performed as described in our previous papers (160, 
161). In brief, cells were cross-linked with 1% formaldehyde for 10 min and 
stopped by adding 125 mM glycine. The isolated nuclei were resuspended in 
nuclei lysis buffer (50 mM Tris pH 8.0, 10 mM EDTA, 1% SDS) and sonicated 
using a Bioruptor Sonicator (Diagenode) for two cycles. The samples were 
immunoprecipitated with 2–4 μg of the appropriate antibodies overnight at 4 °C. 
Protein A/G beads (Millipore) were added and incubated for 1 hour, and the 
immunoprecipitates were washed twice, each with low-salt (20 mM Tris pH 8.0, 
150 mM NaCl, 2 mM EDTA, 1% Triton X-100 and 0.1% SDS), high-salt (20 mM 
Tris pH 8.0, 500 mM NaCl, 2 mM EDTA, 1% Triton X-100 and 0.1% SDS) and 
LiCl buffer (20 mM Tris pH 8.0, 250 mM LiCl, 1 mM EDTA, 1% NP-40 and 1% 
SDS). DNA was eluted from the beads using elution buffer (50 mM NaHCO3, 1% 
SDS) and then reverse-crosslinked, purified using PCR purification kit (Qiagen). 
The purified DNA was analyzed by quantitative real-time PCR on the ABI 7500-
FAST System using the Power SYBR Green PCR Master Mix (Applied 
Biosystems). The primer sequences for ChIP-qPCR are listed in Table 2. 
For ChIP-seq, the purified DNA was sequenced using the Illumina Solexa 
Hiseq 3000. The raw reads were mapped to human reference genome NCBI 37 
(hg19) or the Drosophila melanogaster genome (dm3) by bowtie v1.1.0, allowing 
up to 1 mismatch. Only uniquely mapped reads were retained for peak calling. 
But before that, we use spike-in normalization for sample size correction as 
previously described (162). For simplicity, the reads were downsampled to keep 
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same spike-in reads count in different samples. Then the ChIP-seq peaks were 
called by MACS v1.4.2 with a cutoff of p ≤1e−8, and clonal reads were 
automatically removed by MACS. The ChIP-seq reads density was determined 
by deepTools v2.3.4, and then the average binding profile and heatmap were 
visualized using R v3.2.3. 
 
2.13 ChIP-western blot 
The ChIP-western blot (ChIP-WB) assay was largely similar to ChIP 
assay. Briefly, cells were cross-linked with 1% formaldehyde for 10 min and 
stopped by adding 125 mM glycine. The isolated nuclei were resuspended in 
nuclei lysis buffer (50 mM Tris pH 8.0, 10 mM EDTA, 1% SDS) and sonicated 
using a Bioruptor Sonicator (Diagenode). Anti-FLAG M2-conjugated agarose 
beads (Sigma) were incubated with sonicated lysates overnight at 4 °C. The 
beads were washed twice, each with low-salt (20 mM Tris pH 8.0, 150 mM NaCl, 
2 mM EDTA, 1% Triton X-100 and 0.1% SDS), high-salt (20 mM Tris pH 8.0, 500 
mM NaCl, 2 mM EDTA, 1% Triton X-100 and 0.1% SDS) and LiCl buffer (20 mM 
Tris pH 8.0, 250 mM LiCl, 1 mM EDTA, 1% NP-40 and 1% SDS), and the bound 
proteins were analyzed by SDS-PAGE and Western blot. 
 
2.14 RNA extraction, reverse transcription (RT), and RT-qPCR 
Total RNA was extracted using an RNeasy plus kit (QIAGEN) and 
reverse-transcribed using an iScrip reverse transcription kit (Bio-Rad). 
Quantitative real-time PCR (qPCR) analyses were performed using Power SYBR 
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Green PCR Master Mix and the ABI 7500-FAST Sequence Detection System 
(Applied Biosystems). Gene expressions were calculated following normalization 
to GADPH levels using the comparative Ct (cycle threshold) method. The primer 
sequences for RT-qPCR are listed in Table 2. 
 
2.15 Cell proliferation assay 
 Cells were seeded into a 96-well plate for 200~500 cells in 100 µL 
medium per well in triplicate for each time point and their proliferation was 
measured every one or two days depending on the growth rate of those cells. 
There is a tight linear relationship between cell number and the concentration of 
ATP measured in cell lysate. The bioluminescence-based reagents such as 
CellTiter-Glo (Promega) can detect ATP, which provides a sensitive readout of 
cell proliferation. For proliferation measurement, directly add 25 µL CellTiter-Glo 
into each well and gently rock the plate for 2 minutes on an orbit shaker to induce 
cell lysis. Then incubate the plate at room temperature for 10 minutes to stabilize 
luminescent signal before reading it using Fluostar Omega plate reader. 
 
2.16 Statistical analyses  
Data were presented as mean ± s.e.m. unless stated otherwise. Statistical 
significance was calculated by two-tailed unpaired t-test on two experimental 
conditions with P < 0.05 considered statistically significant unless stated 
otherwise. Statistical significance levels are denoted as follows: *P < 0.05; **P < 
0.01. No statistical methods were used to predetermine sample size. 
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Figure 8. The expression, purification and peptide microarray analysis of 
p300 ZZ domain.  
(A) Schematic representation of full-length p300 protein and the prokaryotic 
expression vector of p300 ZZ domain. (B) SDS-PAGE analysis of GST-tagged 
p300 ZZ domain before and after purification. The arrow points out the band for 
GST-p300ZZ. IPTG: isopropyl β-D-1-thiogalactopyranoside. FT: flow-through. (C) 
The histone peptide microarray probed with GST-tagged p300 ZZ domain. 
Histone peptides were printed in triplicate with their names labeled on the left or 
right. 
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Chapter 3. The ZZ Domain of p300 Recognizes Histone H3 to Regulate 
Chromatin Association and Histone Acetylation 
 
Copyright information: 
Contents of Chapter 3.1-3.5 are based on Zhang Y*, Xue Y*, Shi J, Ahn JW, Mi 
W, Ali M, Wang X, Klein BJ, Wen H, Li W, Shi X and Kutateladze TG. 2018. The 
ZZ domain of p300 mediates specificity of the adjacent HAT domain for histone 
H3. Nat Struct Mol Biol. 25: 841–849. (*: Co-first authors). According to this 
journal, authors retain the rights “to reproduce the contribution in whole or in part 
in any printed volume (book or thesis) of which they are the author(s)”.  
 
3.1 p300 ZZ domain is a reader for histone H3 
To determine the function of p300 ZZ domain in histone binding, we 
performed histone peptide microarray using the GST-tagged p300 ZZ domain. 
GST-p300 ZZ showed a molecular weight ~32 kDa on SDS-PAGE (Figure 8A, 
8B). On the histone peptide microarray, p300 ZZ bound to the unmodified H31-21 
peptide and the H31-21 peptides containing mo-, di-, or tri-methylation on H3K4 or 
H3K9, or symmetric (me2S) or asymmetric dimethylation (me2A) on H3R2 or 
H3R17 (Figure 8C), suggesting that the ZZ domain is able to recognize H3 N-
terminal tail independent of methylation on these residues. 
To determine whether p300 ZZ domain specifically binds to histone H3 but 
not other histones, we performed calf thymus histone pull-down assays using 
GST-tagged p300 ZZ domain (Figure 9A). A known histone H3 reader, RBP2 
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PHD1 domain (163), was used as a positive control. The GST protein was used 
as a negative control. Western blots using specific histone antibodies revealed 
that similar to RBP2 PHD1, p300 ZZ specifically pulled down H3, but not other 
histones. Under the same condition, GST alone did not bind to any histone. 
These results demonstrate that p300 ZZ domain is a histone H3-specific reader.   
To identify the minimal region of H3 tail required for p300 ZZ binding, we 
performed histone peptide pull-down using various fragments of histone H3 
(Figure 9B). Consistent with the microarray data, p300 ZZ domain bound strongly 
to the H31-22 peptide. The H31-8 peptide retained sufficient binding to p300 ZZ. 
However, deletion of the first 4 amino acids from the N-terminus of H3 abolished 
its binding to p300 ZZ. As expected, other H3 regions did not bind to p300 ZZ. 
A number of residues on the histone H3 tail can be post-translationally 
modified, more frequently with methylation and acetylation. To determine 
whether methylation or acetylation on histone H3 affects p300 ZZ binding, we 
performed histone peptide pull-down using histone peptides bearing methylation 
or acetylation on various residues (Figure 10A). Consistent with the microarray 
data, methylation or acetylation did not affect the binding of p300 ZZ domain to 
the H3 tail. Furthermore, p300 ZZ did not bind to other regions of histone H3 or 
H4, regardless of PTMs. Tryptophan fluorescence measurements revealed a Kd 
value of 8.8 μM of p300 ZZ domain for unmodified H31-12 peptide, and 7.7 μM or 
7.6 μM for the H3K4me3 or H3K4ac peptide, respectively (Figure 10B). All 
together, these results demonstrate that the ZZ domain of p300 is a H3-specific 
reader that is insensitive to histone modifications.  
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Figure 9. The ZZ domain of p300 binds to histone H3 tail.  
(A) Calf thymus histone pull-down assays of p300 ZZ domain. RBP2 PHD1 or 
GST was used as a positive or negative control, respectively. (B) Peptide pull-
down assays of p300 ZZ domain using the indicated histone H3 peptides. 
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Figure 10. Recognition of H3 by p300 ZZ domain is not sensitive to 
methylation or acetylation on H3.  
(A) Peptide pull-down assays of the p300 ZZ domain with the indicated histone 
peptides. (B) Binding affinities of p300 ZZ domain for the indicated histone 
peptides measured by tryptophan fluorescence. The experiments were carried 
out in triplicate for H3 and H3K4ac and in duplicate for methylated H3 by Yi 
Zhang from the Kutateladze lab at University of Colorado.  
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3.2 The structural basis of H3 recognition by p300 ZZ domain 
Through collaboration with Dr. Tatiana Kutateladze’s lab at University of 
Colorado School of Medicine, we determined the crystal structure of the p300 
ZZ-H3 complex at 2.0 Å resolution. The complex structure was obtained using a 
chimeric construct containing residues 1-6 of H3 linked to residues 1663-1713 of 
p300. The structure showed that two H3-ZZ fusion proteins form complexes in 
which the H3 region of one molecule is bound to the ZZ domain of another 
molecule (Figure 11A). The p300 ZZ domain adopts a cross-brace topology 
stabilized by two zinc-binding clusters, a couple of twisted two- and three-
stranded anti-parallel -sheets, and a short -helix (Figure 11B). The histone 
residues pair with the first -strand (residues 1665-1669 of ZZ), creating the third 
anti-parallel -stand and make extensive intermolecular contacts with the domain 
(Figure 11B). Characteristic -sheet interactions are observed between the 
backbone amides of Ala1, Thr3 and Gln5 of H3 and T1669, V1667 and R1665 of 
the ZZ domain. Ala1 occupies a highly negatively charged binding site where the 
NH3+ group of Ala1 is anchored through the hydrogen bonds with T1669 and 
N1671 and a salt bridge with D1690 (Figure 11C, D). The guanidinium moiety of 
Arg2 is restrained via a salt bridge with the carboxyl group of D1688 and 
hydrogen bonds with the backbone carbonyl oxygen of E1687, whereas the 
backbone amide of Arg2 is involved in direct and water-mediated hydrogen 
bonding contacts with D1688. The side chain of Lys4 lays in a groove formed by 
the aromatic ring of F1666 and the side chain of D1664, the negatively charged 
carboxylic group of which forms a salt bridge with the -amino group of Lys4 
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(Figure 11B, E). The formation of the salt bridge most likely accounts for the 
indifference of p300 ZZ domain towards PTMs on H3K4, which would augment 
cation- and hydrophobic interactions with F1666 but diminish the electrostatic 
contact with D1664. The side chain of Gln5 is hydrogen bonded to the 
guanidinium group of R1665 (Figure 11E).  
This structural mechanism for the recognition of H3 distinguishes p300 ZZ 
domain from all currently known histone H3 readers. For example, BHC80 PHD 
finger, a H3 reader domain specifically recognizing K4-unmodified H3 tail (164), 
also forms a negatively charged cavity to bind the Ala1 of H3 (Figure 11F). 
However, this binding cavity is located on the opposite side of this domain as 
compared with p300 ZZ (Figure 11C). In addition, unlike ZZ, BHC80 PHD 
contains another site with negative charge to accommodate unmodified Lys4 
(Figure 11F). Methylation on Lys4 disrupts its binding to this negatively charged 
site of BHC80 PHD (164), but does not affect its interaction with p300 ZZ domain 
because ZZ does not have this Lys4-accomadating site (Figure 11C). Therefore, 
the molecular basis of ZZ-H3 interaction indicates that the ZZ domain represents 
a novel family of histone readers. 
 Substitution of N1671, D1688 or D1690, the ZZ domain residues that are 
responsible for binding Ala1 and Arg2 of H3, with an alanine or lysine, abolished 
the ZZ-H3 interaction in peptide pull-down or calf thymus histone pull-down 
assays (Figure 12A, B). Further, mutation of D1664, F1666 or Y1668 also 
substantially reduced the binding, pointing to the essential role of the Lys4 
coordination (Figure 12A, B). 
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Figure 11. Structure of the p300 ZZ-H3 complex. 
(A) The crystal structure of the linked H3-ZZ construct. (B) A ribbon diagram of 
the p300 ZZ domain (light blue) in complex with histone H3 tail (residues 1-6) 
(orange). (C) Electrostatic surface potential of p300 ZZ domain is colored blue 
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(positive charge) and red (negative charge) with the bound histone H3 tail shown 
in stick (green). (D) Zoom-in view of the histone H3 Ala1 binding site. (E) Zoom-
in view of the histone H3 Lys4 binding site. (F) The electrostatic surface potential 
plot of the PHD finger of BHC80 recognizing the N-terminal sequence of histone 
H3 (PDB: 2PUY) (164). 
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Figure 12. Key residues required for ZZ-H3 binding. 
(A) Peptide pull-down assays using wild type and mutated p300 ZZ domain. (B) 
Calf thymus histone pull-down assays of the wild type p300 ZZ domain and the 
indicated mutants. 
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3.3 Recognition of H3 by the ZZ domain is required for p300-chromatin 
association 
Our in vitro data reveal that p300 ZZ domain specifically recognizes the 
histone H3 tail. However, whether the ZZ-H3 interaction is important to the 
functions of p300 in cells is unknown.  
First, we asked the question whether the H3 recognition by ZZ is required 
for p300-chromatin association. To address this question, we attempted to 
determine the chromatin occupancy of the full-length wild-type (WT) p300 or ZZ-
mutants in cultured cells. We cloned the full-length coding DNA sequences 
(CDS) of EP300 gene into either lentiviral vector (pCDH) or retrovirial vector 
(pBABE), and delivered the expressing vectors into H1299 cell line through viral 
infection. Unfortunately, the stable cells thus established failed to express full-
length p300, likely due to the failure of the viruses in packaging the extra-large 
CDS (7.2 kb) of p300.  
To overcome this difficulty, we decided to use the p300 core fragment 
(p300BRPHZT) that contains the BRD, RING, PHD, HAT, ZZ and TAZ2 domains 
(Figure 13A) in our experimental system. The p300BRPHZT fragment cloned in the 
pCDH-3XFLAG vector can be successfully introduced and stably expressed in 
H1299 cells at a reasonable expression level. Therefore, using this p300BRPHZT 
core fragment, we deleted the individual BRD, ZZ, AIL or BRD+ZZ to evaluate 
the importance of these domains to chromatin binding of the p300 core fragment 
in cells (Figure 13A).  
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We performed salt fractionation assay in the cells stably expressing WT 
p300BRPHZT fragment or its counterparts with individual domain deleted (Figure 
13B). The more tightly a protein binds to chromatin, the higher salt concentration 
is needed to wash it off from chromatin. WT p300BRPHZT bound strongly to 
chromatin in cells, as wash buffer containing 0.6 M salt was needed to 
completely wash it off from chromatin. In contrast, ZZ- or BRD-deleted fragments 
bound more weakly to chromatin, as 0.3 M salt can wash them off from 
chromatin. The BRD of p300 is known to bind acetylated histones, preferentially 
acetylated H4 (27). It has been reported that BRD is required for p300 to form 
stable interaction with chromatin (165). The reduced chromatin binding as a 
result of BRD deletion in our salt fractionation assays is consistent with the 
published data. Importantly, simultaneous deletion of both BRD and ZZ domain 
caused a more profound decrease in chromatin binding than single deletions, 
implying an additive effect. As expected, deletion of AIL did not affect chromatin 
binding (Figure 13B). 
 Next, we performed chromatin immunoprecipitation (ChIP) using FLAG 
M2 antibody followed by western blotting (ChIP-WB) of histone H3 to evaluate 
chromatin association of the p300BRPHZT core fragment and the domain-deletion 
mutants (Figure 13C). All FLAG-tagged p300 fragments were expressed at a 
similar level, while the amount of histone H3 pulled down by the ZZ- or BRD-
deletion mutants was much less than that of the WT p300BRPHZT, indicating that 
loss of either domain reduces chromatin binding. Deletion of both domains led to 
a further reduction whereas AIL deletion had little effect. All together, these 
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results suggest that both ZZ and BRD are required for p300-chromatin 
association. 
To further determine the importance of the H3-binding activity of the ZZ 
domain in p300-chromatin association, we introduced histone-binding deficient 
point mutations (N1671A and D1690A, named as ZZmu1 and ZZmu2) into the 
p300BRPHZT fragment (Figure 14A). A BRD point mutant, N1132A (named as 
BRDmu), that fails to bind histone acetylation (27) was also tested. In addition, 
we also constructed p300 fragment carrying D1690A and N1132A double 
mutations (named as ZZmu+BRDmu).  
Both salt fractionation and ChIP-Western assays revealed that mutation of 
either domain reduced p300BRPHZT binding to chromatin and mutations of both 
showed a more severe defect (Figure 14B, C), suggesting that the H3-binding 
activity of the ZZ domain and the histone acetylation binding activity of BRD are 
both required for chromatin association of p300 in cells.   
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Figure 13. Both ZZ domain and BRD are required by p300 for chromatin 
association. 
(A) Schematic representation of full-length p300 protein and the p300 fragments 
stably expressed in H1299 cells. (B) Salt fractionation of H1299 cells stably 
expressing wild type or deletion-mutated FLAG-p300BRPHZT. The workflow for salt 
fractionation assay is shown in Figure 7.	 (C) ChIP-WB analysis of wild type or 
deletion-mutated FLAG-p300BRPHZT in H1299 stable cells. 
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Figure 14. Both the H3-recognition ability of ZZ domain and the acetyllysine 
binding activity of BRD are required by p300 for chromatin association. 
(A) Schematic representation of full-length p300 protein and the p300 fragments 
stably expressed in H1299 cells. (B) Salt fractionation of H1299 cells stably 
expressing wild type or mutated FLAG-p300BRPHZT. The workflow for salt 
fractionation assay is shown in Figure 7.	 (C) ChIP-WB analysis of wild type or 
mutated FLAG-p300BRPHZT in H1299 stable cells. 
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3.4 Recognition of H3 by the ZZ domain facilitates the acetylation of H3K18 
and H3K27 by the HAT domain 
Both BRD and the ZZ domain of p300 are adjacent to the catalytic HAT 
domain. As we discussed in Chapter 1.2, recognition of acetylated histone H4 by 
BRD increases the accessibility of nucleosome substrates to CBP/p300 HAT 
domain, thus contributing to histone acetylation (39). So we speculated that ZZ 
may regulate the enzymatic activity of HAT through a similar mechanism. 
To test this hypothesis, we purified recombinant GST-tagged p300BRPHZ 
fragment (encompassing BRD, RING, PHD, HAT and ZZ domains) and the same 
fragment bearing various deletions/mutations (Figure 15A) and compared their 
enzymatic activity on nucleosomes by in vitro HAT assays. These 
deletions/mutations include ZZ domain deletion, AIL deletion, HAT catalytic dead 
mutation D1399A (HATmu) (166), ZZ domain mutations N1671A or D1690A 
(named as ZZmu1 or ZZmu2, respectively), BRD mutation N1132A (BRDmu), 
D1690A and N1132A double mutations (ZZmu+BRDmu). All the mutations or 
deletions did not affect the protein stability during purification.   
Next we used these fragments as enzymes and recombinant 
mononucleosomes (without pre-existing modifications) as substrate for in vitro 
HAT assays. Equal molar amount of each fragment was used in the assays for 
easy comparison (Figure 15B). Samples were collected at different time points: 
0, 10, 20, 40, 60 and 80 min after reaction, and immunoblotted using specific 
antibodies against H3K4ac, H3K9ac, H3K18ac, and H3K27ac. Total H3 was also 
blotted as a loading control. The fluorescence intensity of each band was 
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measured using Odyssey system. To compare signals from different gels, we 
used pre-modified nucleosomes as a standard to run on each SDS-PAGE gel.  
All values of fluorescence intensity across different gels were compared to the 
common standard sample. All quantifications were based on three biological 
replicates.  
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Figure 15. The p300 fragments used in in vitro HAT assays. 
(A) Schematic representation of p300 fragments used in in vitro HAT assays. (B) 
Western blot analysis showing equal amount of p300 fragments used in the HAT 
assays. 
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As shown in Figure 16, histone acetylation signals gradually increased 
during the time course, indicating the accumulation of products of the HAT 
reaction. All four lysine residues tested, H3K27, H3K18, H3K9 and H3K4, can be 
acetylated by the WT p300BRPHZ enzyme in vitro. Interestingly, deletion of ZZ 
domain greatly reduced acetylation on H3K27 and H3K18 (Figure 16A, B) but not 
on H3K9 and H3K4 (Figure 16C, D), suggesting that the ZZ domain is required 
for efficient acetylation specifically on H3K27 and K18.  
It has been previously reported that deletion of AIL can release the active 
site creating a constitutively active HAT (28). Consistent with this, we found 
deletion of AIL dramatically accelerated the acetylation at all lysine residues at 
early time points such as 10, 20 and 40 min (Figure 16A-D). At 80 min, the 
histone acetylation levels were comparable between reactions with WT and AIL-
deleted enzymes, implying that all substrates were fully acetylated at the last 
time point. This is in agreement with a previously proposed model that the 
hypoacetylated AIL contacts a negatively charged patch on the HAT domain 
surface blocking the active site, whereas acetylation of AIL by HAT releases the 
inhibitory loop, thus freeing the active site (28, 31). As a negative control, HAT 
domain mutation D1399A abolished the acetylation of all sites tested. 
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Figure 16. Deletion of ZZ domain specifically attenuated the acetylation of 
H3K27 and H3K18. 
H3K27ac (A), H3K18ac (B), H3K9ac (C), H3K4ac (D) and H3 (E) western blot 
analysis of	in vitro HAT assays using WT p300BRPHZ or its counterpart harboring 
either ZZ deletion, AIL deletion or loss-of-catalytic activity HAT mutation 
(D1399A), and the reconstituted mononucleosome. Quantification of the HAT 
activity on each lysine was based on the fluorescence signal from three biological 
replicates. A common standard sample is used for normalization in each 
replicate.  
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To further determine whether the regulatory role of ZZ on the HAT activity 
of p300 is dependent on its H3-binding capability, we carried out the same in 
vitro HAT assays to compare WT and ZZ-mutated p300BRPHZ fragment (ZZmu1 or 
ZZmu2) (Figure 17). BRDmu and ZZmu+BRDmu were also included as controls. 
Similar to deletion of ZZ, ZZ point mutations exhibited a much lower HAT activity 
on H3K27 and H3K18 (Figure 17A, B), whereas acetylation of H3K9 and H3K4 
were not reduced compared to the WT p300 fragment (Figure 17C, D). Different 
from ZZ mutations that specific attenuated H3K18 and H3K27 acetylation, BRD 
mutation led to a substantial decrease in acetylation of all lysine residues tested 
(Figure 17A-D). Furthermore, double mutations of both ZZ and BRD totally 
abolished the acetylation of all tested residues (Figure 17A-D). Together, these 
results suggest that the acetyllysine binding function of BRD is necessary for the 
overall catalytic activity of p300BRPHZ on histones, whereas recognition of H3 by 
ZZ domain is specifically required for p300BRPHZ to acetylate H3K18 and H3K27. 
Mutations simultaneously disrupting the functions of both domains may 
completely disable p300’s access to nucleosomes, abolishing acetylation of all 
histone substrates.
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Figure 17. H3 binding by ZZ domain facilitates p300 HAT activity on H3K18 
and H3K27. 
H3K27ac (A), H3K18ac (B), H3K9ac (C), H3K4ac (D) and H3 (E) western blot 
analysis of	in vitro HAT assays using WT or mutated p300BRPHZ and the 
reconstituted mononucleosome. Quantification of the HAT activity on each lysine 
was based on the fluorescence signal from three biological replicates. A common 
standard sample is used for normalization in each replicate.  
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Because the first two residues of H3 (Ala1-Arg2) are critical to the ZZ-H3 
interaction, we speculated that the very N-terminal residues of H3 are also 
required for the acetylation of H3K18 and H3K27 by p300 HAT. To test this 
hypothesis, we carried out in vitro HAT assays of the WT p300BRPHZ fragment 
using recombinant mononucleosomes containing full-length H3 (rNUC_H3_FL) 
or H3 with the first two amino acid residues deleted (rNUC_H3_∆N). We found 
that the removal of Ala1-Arg2 of histone H3 dramatically decreased acetylation of 
H3K27 and H3K18 by p300 HAT (Figure 18A-B), likely due to the reduced ZZ-H3 
interaction. However, since each nucleosome contains two H3 subunits, this 
experiment cannot distinguish whether the recognition of H3 by p300 ZZ 
facilitates the acetylation of K27 and K18 on the same H3 subunit (in cis) or on 
the other H3 subunit in the same or adjacent nucleosomes (in trans). To clarify 
this mechanism, we performed in vitro HAT assays using histone peptides as 
substrates. We incubated the WT p300BRPHZ with the H31-33 peptide or the same 
H3 peptide with the first two amino acids deleted (H33-33). Similar to the results of 
the HAT assays on mononucleosomes, p300BRPHZ catalyzed H3K18ac and 
H3K27ac more efficiently on H31-33 than on H33-33 (Figure 18C), supporting the in 
cis model (but not excluding the in trans model).  
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Figure 18. The first two residues of H3 are required for the acetylation of 
H3K18 and H3K27. 
(A) In vitro HAT assays using WT p300BRPHZ and the reconstituted 
mononucleosome carrying either intact H3.1 (rNUC_H3_FL) or N-terminally 
truncated H3.1 (rNUC_H3_∆N, Ala1 and Arg2 of both H3.1 are deleted). (B) 
Quantification of the HAT activity on H3K18 and H3K27 based on the 
fluorescence signal in (A) from three biological replicates. The 1 hr sample of 
rNUC_H3_FL is used for normalization. (C) In vitro HAT assays using WT 
p300BRPHZ and biotinylated H3 peptides.  
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The in vitro HAT assays demonstrate that recognition of H3 by the ZZ 
domain is required for the HAT domain of p300 to acetylate histone on H3K18 
and H3K27. Next we asked whether this recognition has the same regulatory role 
in cells. To address this question, we utilized the H1299 stable cells systems 
established in Chapter 3.3 and evaluated global histone acetylation levels of 
these H1299 cells by Western bot analysis. First, we compared various H3 and 
H4 acetylation levels in the cells stably expressing WT FLAG-p300BRPHZT, ZZ, 
BRD, or AIL deletion mutants as well as ZZ and BRD double deletion mutants 
(Figure 19A). The Western blotting band intensities were quantified using 
Odyssey and normalized by total H3 or H4 values. Heatmaps were generated 
using the mean values of fold changes relative to the vector controls from three 
biological replicates (Figure 19B). Compared with the control cells infected with 
an empty vector, WT p300BRPHZT-expressing cells showed higher levels of global 
H3K4ac, H3K18ac, H3K27ac and H4 tetra-acetylation (5~8-fold) and a 
moderately higher H3K9ac level (~2-fold) (Figure 19A, B). Compared with the 
WT p300BRPHZT-expressing cells, BRD deletion markedly reduced the acetylation 
levels on all sites tested. In contrast, deletion of the ZZ domain specifically 
decreased H3K18ac and H3K27ac levels, whereas the levels of H3K4ac, 
H3K9ac or H4ac remained largely unchanged. Deletion of both ZZ and BRD 
further reduced acetylation on H3K18 and H3K27 to an undetectable level 
(Figure 19A, B). These results suggest that both BRD and the ZZ domain are 
required for maintaining H3K18 and H3K27 acetylation in cells. Unlike the in vitro 
HAT assays results, deletion of AIL did not dramatically change the acetylation 
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levels of any site in cells (Figure 19A, B). One possible explanation is that the AIL 
region of the ectopic p300BRPHZT fragment is hyperacetylated and stretching out 
from the HAT active site, thus having a minimal inhibitory effect. 
The results above demonstrate that while BRD is required for acetylating 
all lysine residues, the ZZ domain is specifically required by p300 in acetylating 
H3K18 and H3K27 in cells. Next, we sought to determine whether the importance 
of ZZ and BRD in histone acetylation is dependent on their histone-binding 
capabilities. In this regard, we compared the global histone acetylation levels of 
H1299 cells stably expressing WT FLAG-p300BRPHZT and those expressing 
FLAG-p300BRPHZT bearing point mutations in ZZ, BRD or both domains. Similar to 
their respective deletion mutants, the BRD mutant failed to acetylate almost all 
histone H3 and H4 lysine residues tested, and the two ZZ point mutations were 
specifically defective in acetylating H3K18 and H3K27 (Figure 19C, D). Mutations 
in both domains led to a more severe drop in H3K18ac and H3K27ac levels 
compared to the ZZ or BRD single domain mutations (Figure 19C, D).  
Furthermore, in a transient expression system expressing full-length p300 
in 293T cells, introducing the loss-of-function mutations into the ZZ domain also 
attenuated the full-length p300 in acetylating H3K18 and H3K27 (Figure 20A, B). 
Together, these findings reveal that recognition of H3 by the ZZ domain plays a 
critical role in facilitating p300-mediated H3K18 and H3K27 acetylation in cells 
whereas the binding of acetylated histone by BRD is required for the acetylation 
of all lysine residues on H3 and H4.  
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Figure 19. H3 recognition by ZZ domain is critical to p300-mediated H3K18 
and H3K27 acetylation in cells. 
(A) Western blot analysis of histone acetylation levels in whole cell extract of 
H1299 cells stably expressing wild type or deletion-mutated FLAG-p300BRPHZT. 
(B) Heatmap of quantification of the indicated histone acetylation levels from 
three biological replicates as in (A). Total H3 or H4 was used for normalization. 
(C) Western blot analysis of histone acetylation levels in whole cell extract of 
H1299 cells stably expressing wild type FLAG-p300BRPHZT or the indicated 
mutants. (D) Heatmap of quantification of the indicated histone acetylation levels 
from three biological replicates as in (C). Total H3 or H4 was used for 
normalization. 
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Figure 20. H3 recognition by ZZ domain is required by full-length p300 to 
acetylate H3K18 and H3K27 in cells. 
(A) Western blot analysis of histone acetylation levels in whole cell extract of 
293T cells transiently expressing full-length p300 or the ZZ mutants. (B) 
Quantification of the indicated histone acetylation levels from three biological 
replicates as in (A). Total H3 was used for normalization.   
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3.5 Recognition of H3 by the ZZ domain is required for genome-wide p300 
occupancy and p300-dependent deposition of H3K18ac and H3K27ac  
To gain a deeper insight into the role of p300 ZZ domain in regulating 
p300 occupancy and p300-dependent deposition of H3K18ac and H3K27ac 
genome-wide, we performed ChIP-seq analysis in H1299 cells stably expressing 
FLAG-p300BRPHZT or its counterpart harboring ZZ loss-of-function mutations, 
N1671A or D1690A (Figure 21A-C). Western blotting analysis showed that the 
WT and mutant FLAG-p300BRPHZT fragments are expressed at similar levels 
(Figure 21B). We used the anti-Flag M2 antibody to ChIP for FLAG-p300BRPHZT 
fragments and anti-H3K18ac and anti-H3K27ac antibodies to ChIP for respective 
histone acetylation. The ChIPed DNA was sequenced using the Illumina Solexa 
Hiseq 3000 at MD Anderson Cancer Center Science Park Next-Generation 
Sequencing (NGS) Facility. We collaborated with Jiejun Shi from Dr. Wei Li’s lab 
in Baylor College of Medicine (BCM) to analyze the ChIP-seq data. Our lab’s 
previous data of anti-H3K4me1, anti-H3K27me3 and anti-H3K27ac ChIP-seq in 
parental H1299 cells were also used in our analysis.  
Anti-FLAG ChIP in the cells expressing WT FLAG-p300BRPHZT identified 
679 p300BRPHZT binding sites. Compared with the previously published full-length 
p300 binding sites (25, 167), p300BRPHZT binding sites are much broader and the 
peaks are less sharp. To ensure to include the majority of p300BRPHZT binding 
sites, we analyzed ChIP-seq signals spanning a ± 20 kb window centered on 
binding peaks (Figure 21D). Based on pre-existing PTMs on H3K27 in H1299 
cells, we divided the p300BRPHZT binding sites into two groups: H3K27 pre-
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acetylated regions (Group 1) and H3K27 pre-methylated regions (Group 2) 
(Figure 21D). Group 1 sites are enriched with H3K27ac and H3K4me1, indicating 
they are probably active enhancers and are likely targets of endogenous 
p300/CBP. Because the peaks are already hyperacetylated, ectopic expression 
of the p300BRPHZT fragment is not able to further increase acetylation levels at the 
peaks. In contrast, a significant increase in H3K18ac and H3K27ac levels at the 
hypoacetylated peak flanking regions was observed when ectopically expressing 
WT p300BRPHZT (compared with the control cells expressing an empty vector) 
(Figure 21D, Figure 22). Group 2 binding sites are preoccupied by H3K27me3 
but not by H3K27ac or H3K18ac. This is not surprising as it has been shown 
previously that p300/CBP also bind to a large number of poised regulatory 
regions that are low in H3K27ac and high in H3K27me3 (167-169). Because 
H3K27 at these regions is largely methylated across the entire +/- 20 kb windows 
thus less accessible to p300 HAT, no significant increase in H3K18ac or 
H3K27ac level was observed, despite the strong binding of p300BRPHZT in these 
regions (Figure 21D).  
In contrast to the WT p300BRPHZT protein, the two ZZ domain mutants, 
N1671A and D1690A, were much less capable of gaining the chromatin binding 
at both groups of sites, and consequently, the increase in H3K18ac and 
H3K27ac occupancies at those sites was attenuated in the cells expressing 
these mutants (Figure 21D, Figure 22).  
We show in Figure 23 genome-browser views of four representative p300-
bound genes: NBPF1, NOTCH2NL, PDE4DIP and DMPK. While endogenous 
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histone acetylation is strongly enriched at gene promoters, FLAG-p300BRPHZT 
binds to much broader regions not only at promoters, but also in gene bodies and 
intergenic regions. Binding of p300BRPHZT enhanced local histone acetylation 
levels on both H3K18 and H3K27. However, loss-of-function mutations in ZZ 
domain abolished p300BRPHZT bindings at those regions and consequently, 
impaired acetylation on H3K18 and H3K27. These ChIP-seq results were 
validated by ChIP-qPCR (Figure 24). Notably, the mutations of the ZZ domain 
that abolish its H3-binding ability considerably decreased binding of p300BRPHZT 
to individual genes (Figure 24A) and led to a notable reduction in the H3K18 
(Figure 24B) and H3K27 (Figure 24C) acetylation levels on these genes. In 
contrast, the H3K18 and H3K27 acetylation levels on ASCL1 and INSM1, the 
negative control sites without p300BRPHZT binding, were not significantly changed 
by ZZ mutations.   
Similarly, the N1132A mutation that abrogates acetyllysine binding activity 
of BRD resulted in a drastic decrease in p300BRPHZT occupancy and H3K18ac 
and H3K27ac deposition at NBPF1, NOTCH2NL and DMPK target regions but 
not the negative control regions (Figure 25). However, the p300BRPHZT occupancy 
and H3K18ac and H3K27ac levels of PDE4DIP upstream regions were not 
significantly affected by BRD mutation, indicating the chromatin association and 
histone acetylation of p300BRPHZT are specifically dependent on ZZ-H3 
recognition but not on BRD’s function at this site. 
  Together, these data suggest that both ZZ-H3 and BRD-acetyllysine 
interactions are required for binding of p300 to chromatin and efficient histone 
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H3K18/K27 acetylation in cells, corroborating the findings in salt fractionation 
(Figure 14B), ChIP-WB (Figure 14C), in vitro HAT assay (Figure 17) and in vivo 
histone acetylation analysis (Figures 19-20) described above.  
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Figure 21. The ZZ domain is necessary to p300’s chromatin binding and 
acetylation activity on H3K18 and H3K27 in cells. 
(A) The workflow of samples preparation for ChIP-seq assay. (B) Western blot 
analysis of the expression levels of wild type or mutated FLAG-p300BRPHZT level. 
(C) Electrophoresis of sonicated DNAs for ChIP-seq. (D) Heatmap of normalized 
H3K27ac (purple), H3K4me1 (green), H3K27me3 (scarlet), FLAG (brown) and 
H3K18ac (blue) ChIP-seq signals centered on FLAG binding sites in a ±20kb 
window in H1299 control cells and H1299 cells stably expressing wild type 
FLAG-p300BRPHZT or the indicated ZZ mutants. The color keys represent signal 
density.  
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Figure 22. Box plots comparing FLAG, H3K18ac and H3K27ac occupancies 
in different samples at FLAG-p300BRPHZT binding peaks.  
All FLAG-p300BRPHZT peaks are divided into two groups as in Figure 21D. The 
centerline of box represents the median and box limits indicate the 25th and 
75th percentiles. Two-tailed paired Student’s t-test was used for statistical 
analyses. 
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Figure 23. Representative genome-browser views of ChIP-seq data.  
Representative genome-browser views of the FLAG (brown), H3K18ac (blue) 
and H3K27ac (purple) ChIP-seq signals on the indicated genes. The red lines 
indicate the sites for ChIP-qPCR validation.  
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Figure 24. ChIP-qPCR in H1299 cells stably expressing wild type FLAG-
p300BRPHZT or the ZZ mutants. 
qPCR analysis of the FLAG-p300BRPHZT, H3K18ac and H3K27ac ChIP at target 
loci (locations indicated by red line in Figure 23) and two negative control loci in 
H1299 cells stably expressing wild type FLAG-p300BRPHZT or the ZZ mutants. IgG 
or H3 ChIP was used for normalization. 
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Figure 25. ChIP-qPCR in H1299 cells stably expressing wild type FLAG-
p300BRPHZT or the BRD mutant. 
qPCR analysis of the FLAG-p300BRPHZT, H3K18ac and H3K27ac ChIP at target 
loci and two negative control loci in H1299 cells stably expressing wild type 
FLAG-p300BRPHZT or the N1132A mutant. IgG or H3 ChIP was used for 
normalization. 
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3.6 Conclusions 
Our studies identify the ZZ domain of p300 as a reader specifically 
recognizing the N-terminus of histone H3. This recognition is insensitive to 
methylation or acetylation on H3 tail, a binding pattern distinct from all known H3 
readers, suggesting the ZZ domain may constitute a novel group of histone 
readers. Crystal structure of the ZZ-H3 complex reveals a negatively charged 
cavity of ZZ that coordinates Ala1 and Arg2 of H3, suggesting a novel recognition 
mode.   
The H3-binding capability of ZZ and the acetyllysine binding ability of BRD 
are both essential for chromatin association of p300 and acetylation of histones. 
Specifically, the BRD-acetyllysine binding is necessary for p300 to catalyze 
acetylation of virtually all lysine residues in H3 and H4, whereas the ZZ domain is 
specifically required for p300 to acetylate primarily H3K27 and H3K18. 
Collectively, the binding of p300 ZZ domain to H3 N-terminus provides a novel 
intramolecular mechanism in regulating both chromatin recruitment and substrate 
selectivity of p300. 
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3.7 Discussion 
Transcriptional coactivators p300 and CBP play critical roles in multiple 
fundamental cellular processes such as cell proliferation, differentiation and 
apoptosis. They contain multiple domains and most of these domains have been 
well studied. However, the function of their ZZ domain is still elusive. In this 
study, we discover that p300 ZZ domain is a reader for histone H3. It specifically 
recognizes the first a few residues of H3 N-terminus, regardless of methylation or 
acetylation status on H3. This unique feature distinguishes ZZ from all known 
readers, as other readers are all sensitive to histone PTMs. The Kd value for the 
p300 ZZ-H3 interaction is 8.8 μM (Figure 10B), which is in the range of binding 
affinities exhibited by the majority of histone-binding modules (170-172), 
corroborating the notion that the ZZ domain of p300 is a new member of 
epigenetic readers that select for histone H3.  
The ZZ domain of p300 possesses a novel structural mechanism for 
histone H3 recognition. Importantly, key residues forming the negatively charged 
binding site to contact with the Ala1 and Arg2 of H3, such as N1671, D1688 and 
D1690, are highly conserved in multiple members of ZZ domain family (Figure 
4B).  It will be interesting to test whether other ZZ domains containing these 
conserved residues also have H3-binding ability. 
Although coactivator functions of p300/CBP are largely dependent on their 
chromatin-binding capability (165, 173), the mechanism underlying p300/CBP-
chromatin association is not well studied. Transcription factors that bind specific 
DNA sequences and other chromatin-binding factors can recruit p300/CBP to 
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chromatin through protein-protein interaction (46). Independent of the recruitment 
by other proteins, p300 itself can directly bind to chromatin (165), which requires 
the acetyllysine-binding ability of p300 BRD. We found that recognition of H3 by 
p300 ZZ domain is also required for p300-chromatin association, which provides 
another mechanism for recruiting p300 to chromatin. By ChIP and salt 
fractionation assays, we revealed the importance of ZZ and BRD for p300’s 
binding to chromatin, as deletion or loss-of-function mutations of either domain 
dramatically reduced p300-chromatin association globally and at specific target 
regions (Figures 13, 14, 24 and 25). Furthermore, simultaneous mutations of 
both domains further reduced chromatin binding compared with single domain 
deficiencies, indicating that ZZ and BRD may collaborate in promoting p300’s 
chromatin recruitment. Interestingly, double mutations did not completely abolish 
p300’s chromatin binding (Figures 13 and 14), suggesting that mechanisms other 
than ZZ and BRD may exist. For instance, the TAZ2 domain can recruit p300 to 
chromatin through interacting with transcription factors (46). 
Genome-wide analysis of p300BRPHZT occupancy by ChIP-seq analysis 
identified 679 peaks, which are much fewer than that of full-length p300 (25, 
167). This is likely because the p300BRPHZT fragment lacks a number of protein-
interacting domains in the full-length protein that also contribute to p300-
chromatin binding. Nevertheless, the p300BRPHZT binding sites can be classified 
into two groups based on the pre-existing modifications on H3K27: H3K27 pre-
acetylated regions (Group 1) and H3K27 pre-methylated regions (Group 2) 
(Figure 21D). Group 1 sites are likely active enhancers containing high level of 
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H3K4me1 and H3K27ac while Group 2 binding sites are probably silenced or 
poised enhancers. Both BRD and ZZ domains are required for p300 binding at 
both groups of sites, however, certain level of specificity still remains. For 
example, the p300BRPHZT occupies the PDE4DIP upstream region; mutations of 
the ZZ mutation, but not BRD, affect the binding. As H4 acetylation levels may be 
low in this region, it is likely that the ZZ-H3 interaction plays a dominant role in 
p300 chromatin binding. 
Most known histone readers recognize specific histone modifications, thus 
promoting recruitment of the protein or protein complex to specific chromatin loci. 
However, the ZZ-H3 binding is independent of any H3 modifications, suggesting 
that ZZ domain alone is not be able to recruit p300 to specific chromatin regions. 
So, what is the significance of the “non-specific” ZZ-H3 interaction in p300’s 
chromatin recruitment? Inspired by the ideas of Manning et al. (165), we 
proposed the following model (Figure 26). Prior to p300 being recruited to 
specific target regions by interacting with transcription factors, the recognition of 
H3 by ZZ domain may account for the initial step of p300 to associate with 
chromatin (Figure 26A). This close chromatin proximity would allow DNA-bound 
transcription factors to quickly find p300 and then to recruit it to specific target 
regions (Figure 26B). Alternatively, after p300 is recruited to specific regions by 
transcription factors, the ZZ-H3 binding stabilizes p300’s association with 
chromatin to ensure transcription is successfully activated (Figure 26C). More 
biochemical and cell-based experiments need to be done to test this model. 
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Both p300 and CBP are promiscuous acetyltransferases with hundreds of 
substrates, including multiple sites of all core histones (19). However, depletion 
of both p300 and CBP specifically reduces global levels of H3K18ac and 
H3K27ac in mammalian cells (12, 13). The reason why acetylation on H3K18 
and H3K27 is dominantly dependent on p300/CBP is currently unknown. We 
show that the ability of p300 to acetylate primarily H3K18 and H3K27 largely 
relies on the binding of the ZZ domain to the N-terminus of H3. A model of the 
p300HAT+ZZ-H3 complex (generated by Yi Zhang from Kutateladze lab) using the 
simulated annealing method and the crystal structures of p300BRPH and p300 ZZ-
H3 reveals a ~38 Å distance between the H3A1-binding site of ZZ and the 
catalytic site in the HAT domain (Figure 27). This distance is too long for Lys4 or 
Lys9 of H3 to occupy the active site of the HAT domain and thus be acetylated in 
cis when the N-terminus of H3 is locked through the interaction with ZZ. 
However, the distal lysine residues (K18 and K27) in the H3 tail can reach the 
active site. Furthermore, the substrate-binding groove of the HAT domain is 
highly negatively charged and would favor the binding of positively-charged H3 
tail. Our in vitro and in vivo data and the structure model collectively suggest that 
binding of p300 ZZ domain to the N-terminus of H3 provides selectivity of the 
adjacent HAT domain toward the distal lysine sites in H3, such as H3K18 and 
H3K27. 
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Figure 26. The proposed functions of ZZ domain-mediated p300 chromatin 
recruitment. 
(A) Before p300 is recruited to specific target regions by transcription factors, the 
recognition of H3 by ZZ domain may represent the initial step to associate p300 
with chromatin. (B) This association would then allow DNA-bound transcription 
factors to recruit p300 from chromatin, rather than from solution, to specific target 
regions more efficiently. (C) After p300 is recruited to specific regions by 
transcription factors, its interaction with chromatin is stabilized by the ZZ-H3 
binding to ensure transcription is successfully activated. 
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Figure 27. The structural basis of ZZ-mediated HAT specificity toward the 
distal lysine sites in H3. 
A model of the p300HAT+ZZ region in complex with H31-31 peptide generated by Yi 
Zhang from Kutateladze lab. Electrostatic surface potential of p300 HAT is 
colored blue (positive charge) and red (negative charge) with the histone H3 
peptide shown in green. The side chains of H3K4, K9, K18 and K27 are colored 
yellow.  
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Chapter 4. p300 Is Required for Maintenance of SCLC Cell Growth 
 
4.1 Depletion of p300 impedes SCLC cell proliferation 
Cancer cells are highly dependent on dysregulated transcriptional 
programs gained during tumorigenesis to maintain their continued growth, a 
phenomenon called “transcriptional addiction” (174). As transcriptional 
coactivators, p300/CBP have been extensively studied in many types of cancers, 
however, their roles in SCLC are elusive. High p300/CBP expression was 
reported to be associated with poor overall survival for resected SCLC patients 
(111). In SCLC, disease maintenance is addicted to overexpression of 
oncogenes such as MYC, MYCL, MYCN, NFIB and SOX2, which is driven by 
super-enhancers containing extraordinarily high level of H3K27 acetylation (153). 
Considering p300 and CBP are the dominant HATs catalyzing H3K27 
acetylation, they likely play important roles in maintaining active super-enhancers 
in SCLC. Based on these known facts, we hypothesized that p300/CBP are 
required for SCLC disease maintenance by activating oncogenes. 
First, we examined the expression levels of p300/CBP in a number of 
mouse and human SCLC cells. SCLC cells isolated from primary tumors of 
genetically engineered mouse models (GEMM) constitute a good model because 
of their simple genetic background. Kp1 and Kp3 are two primary SCLC tumor 
cell lines isolated from the GEMM with conditional Trp53 Rb1 double knockout in 
lung (175); Kp12 and 259-2 cells are isolated from conditional Trp53 Rb1 p130 
triple knockout GEMM that have accelerated SCLC tumorigenesis compared with 
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Trp53 Rb1 double knockout GEMM (176) (Figure 28A). ID43 cells are lung 
epithelial neuroendocrine cells isolated from conditional Trp53 Rb1 p130 triple 
knockout GEMM before they become malignant (preSC), thus serving as a non-
tumorigenic control for SCLC cells (177) (Figure 28A). By analyzing the whole 
cell lysate of these cells, we found that most GEMM SCLC cells have higher 
p300 levels than the ID43 preSC cells (Figure 28B). The expression levels of 
CBP are also slightly higher in the GEMM SCLC cells. However, despite of the 
increased p300/CBP levels, we did not observe a dramatic elevation of global 
H3K27ac level in GEMM SCLC cells compared with ID43 cell (Figure 28B).  
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Figure 28. p300 is overexpressed in murine SCLC cell lines. 
(A) The sources of GEMM SCLC cell lines. (B) Western blot analysis of p300, 
CBP and H3K27ac levels in the indicated SCLC cell lines. 
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To determine the role of p300/CBP in maintenance of SCLC cell growth, 
we depleted Ep300 or Crebbp gene using a lentiviral CRISPR-Cas9 system. Two 
distinct gRNAs targeting the 5’ end of the CDS were used for each gene and 
non-targeting (NT) gRNA served as control. Western blotting confirmed that each 
target gene was successfully depleted at protein level in all cell lines without 
significantly affecting the level of its close paralog (Figure 29A). Proliferation 
assays showed that p300-depleted Kp1, Kp3, Kp12 and 259-2 cells grow much 
more slowly than their NT control cells (Fig 29B). Compared to p300 depletion, 
CBP depletion had little (Kp1 and 259-2) or no (Kp3 and Kp12) proliferation 
defect (Fig 29B). Together, these results demonstrate that p300, but not CBP, is 
essential to murine SCLC cell proliferation.  
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Figure 29. The depletion of p300 impedes murine SCLC cells proliferation.  
(A) Western blot analysis of p300 and CBP levels in the control and p300/CBP-
depleted murine SCLC cells. (B) The proliferation of control and p300/CBP-
depleted murine SCLC cells. 
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Compared with GEMM SCLC cells, human SCLC cells are much more 
heterogeneous both genetically and epigenetically. For example, they have 
distinct mutation status of CREBBP/EP300 genes, amplification of different MYC 
family genes, and various expression levels of neuroendocrine transcription 
factors. To study the role of CBP/p300 in human SCLC cells with different 
backgrounds, we chose SCLC cells with (1) WT CBP and WT p300 (H69, H82 
and H2171); (2) WT p300 and mutated CBP (H1048 and H209); and (3) WT CBP 
and mutated p300 (H524 and H1836). The detailed mutation information of those 
cells is listed in Table 5. Immortalized human bronchial epithelial cell (HBEC) 
was used as a non-cancer control. Western blot analysis showed that all SCLC 
cell lines except H1836 have much higher levels of p300 than HBEC and all cell 
lines except H209 have greatly increased CBP level compared with HBEC cells 
(Figure 30). Loss of CBP in H209 cell is due to translocation and loss-of-
heterozygosity (LOH) (90, 158). It is interesting that cell lines carrying mutated 
p300 (H524) or CBP (H1048) still had higher levels of p300 and CBP, 
respectively, than control cells. There are two possibilities: (1) the mutations are 
heterozygous and the remaining WT allele is still functional; or (2) the mutations 
do not completely abolish the proteins’ functions. For example, the CBP 
mutation, S1680del, in H1048 cells is not located within any known domain 
(Table 5), therefore its functional consequence is hard to predict. In H524 cells, 
although the mutation in the HAT domain abrogates the HAT activity (95), the 
mutant p300 may still interacts with other proteins to help to assemble an 
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activating complex. Nevertheless, our results suggest that p300 and CBP are 
overexpressed in human SCLC cells regardless of their genetic mutation status. 
We next examined global H3K18ac and H3K27ac levels in these cells 
(Figure 30). Although the levels of H3K27ac in SCLC cells are not significantly 
higher than the non-tumorigenic HBEC cells, H3K18ac levels are much higher in 
the SCLC cells compared with HBEC. The global H3K18ac and H3K27ac levels 
correlate with the total levels of p300 and CBP proteins in most human SCLC 
cells except for the H69 cells.   
 
Cell line Cell type EP300 status CREBBP status 
HBEC Human control cell WT WT 
A549 Human NSCLC WT WT 
H1299 Human NSCLC WT WT 
H1048 Human SCLC WT p.S1680del 
H1836 Human SCLC p.S1396P WT 
H209 Human SCLC WT Homozygous Deletions 
H2171 Human SCLC WT WT 
H524 Human SCLC p.F1090L, Y1503S WT 
H69 Human SCLC WT WT 
H82 Human SCLC WT WT 
ID43 Mouse pre-SCLC WT WT 
Kp1 Mouse SCLC WT WT 
Kp3 Mouse SCLC WT WT 
Kp3+GFP+Luc Mouse SCLC WT WT 
Kp12 Mouse SCLC WT WT 
259-2 Mouse SCLC WT WT 
 
Table 5. The mutation status of EP300 and CREBBP genes in lung cancer 
cell lines used in this study. 
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Figure 30. p300 and CBP are overexpressed in human SCLC cell lines. 
Western blot analysis of p300, CBP, H3K18ac and H3K27ac levels in the 
indicated SCLC cell lines. 
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Human SCLC cells can be classified by the expression levels of NE 
lineage transcription factors, ASCL1 or NEUROD1. ASCL1-high (cells expressing 
high level of ASCL1 but low level of NEUROD1) and NEUROD1-high (cells 
expressing high level of NEUROD1 but low level of ASCL1) are two dominant 
groups (178) that have different epigenetic landscapes (179). To examine the 
role of p300/CBP in both groups of human SCLC cells, we depleted 
CREBBP/EP300 in both ASCL1-high (H69 cells) and NEUROD1-high (H82 cells) 
cells and determined cell proliferation. Two distinct gRNAs targeting the 5’ end of 
the CDS were used for each gene and non-targeting (NT) gRNA served as 
control. Western blotting confirmed that each target gene was successfully 
depleted at protein level in both cell lines without significantly affecting the level 
of its close paralog (Figure 31A). Depleting p300 or CBP did not significantly 
affect the global H3K27ac level in these two cell lines (Figure 31A), suggesting 
the potential redundancy between p300 and CBP in maintaining the global 
H3K27ac level.  
Proliferation assays showed that p300 depletion led to a severe 
proliferation defect in both H69 and H82 cells, whereas CBP depletion only 
slightly impeded cell proliferation (Figure 31B), suggesting that p300, but not 
CBP, is crucial to human SCLC cell proliferation. Those results are in agreement 
with our observations in murine SCLC cells.  
NSCLC is another subtype of lung cancer accounting for ~85% of lung 
cancer cases. To examine whether p300 and CBP are required by NSCLC, we 
depleted EP300 or CREBBP gene in two representative NSCLC cell lines, A549 
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and H1299, and HBEC cell, and measured cell proliferation. Surprisingly, cell 
proliferation was not affected by p300 or CBP depletion in these cell lines (Figure 
32), indicating that the dependency on p300 is specific to SCLC but not to 
NSCLC or normal lung cells.  
In summary, we found that p300 is overexpressed in both murine and 
human SCLC cells. It is required for the maintenance of cell growth in both 
murine and human SCLC cells. Although CBP is also overexpressed in human 
SCLC, but in most SCLC cells, CBP is not absolutely required for cell growth 
maintenance. 
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Figure 31. The depletion of p300 impedes human SCLC cells proliferation.  
(A) Western blot analysis of p300 and CBP levels in the control and p300/CBP-
depleted human SCLC cells. (B) The proliferation of control and p300/CBP-
depleted H69 and H82 cells.  
 
106	
	
 
 
Figure 32. The depletion of p300 does not affect the proliferation of human 
NSCLC cells and normal lung epithelial cell.  
(A) The proliferation of control and p300/CBP-depleted H1299 and A549 cells. 
(B) The proliferation of control and p300/CBP-depleted HBEC cells.  
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4.2 Depletion of p300 attenuates oncogene activation in SCLC cells 
CBP/p300 are critical transcriptional coactivators that control the 
expression of key cancer-related genes, especially those associated with super-
enhancers (103). To determine the functional differences between p300 and CBP 
in SCLC cell proliferation, we assessed the expression of a few key oncogenes in 
p300 or CBP depleted cells. We chose to study the expression changes of MYC 
family genes because: (1) MYC family genes are known to play critical roles in 
the tumorigenesis/maintenance of both murine (177, 180) and human (151, 156) 
SCLCs; (2) MYC family genes are associated with super-enhancers in human 
SCLCs and are thus likely direct targets of p300/CBP (153). MYC family genes 
include 3 members: MYC, MYCL1 and MYCN. A large number of human SCLCs 
have the amplification of one MYC family gene. For example, H69 cell is MYCN-
amplified whereas H82 has MYC amplification. The amplified MYC member 
usually has much higher expression level than the other 2 members and 
becomes the dominant one in that cell (156, 181). We performed RT-qPCR 
assays to compare the expression levels of MYC, MYCL and MYCN in these two 
cell lines (Figure 33A). Consistent with the amplification status, MYC levels in 
H82 are ~1,000-fold higher than that in H69 while its MYCN level was ~1,000-
fold lower than that of H69. We also observed that H82 has higher MYCL1 
expression level than H69. It is possible that among the MYC family members, 
MYCN or MYC plays the most dominant oncogenic role in H69 or H82, 
respectively.  
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Interestingly, in H69, depletion of p300 or CBP reduced the expression of 
MYCN and MYC but not MYCL1. The decrease in MYCN level was much more 
significant in p300-depleted cells than in CBP-depleted cells (Figure 33B). The 
decreased expression of MYCN was also observed in p300- or CBP-depleted 
H82 cells. But the reduction of MYC level was only found in p300-depleted H82 
cells but not in CBP-depleted ones (Figure 33B). These results suggest that 
expression of the dominant MYC family member shows more dependency on 
p300 than CBP in both cell lines. This may partially explain why p300 depletion 
caused much more severe proliferation defect than CBP depletion (Figure 31B). 
According to the work of Drs. Kwok-kin Wong and Richard Young (153), 
MYCN is driven by super-enhancers in H69 but not in H82 while MYC is driven 
by super-enhancers in H82 but not in H69 (Figure 34A), which is consistent with 
their relative expression levels (Figure 33A) and amplification status in these 2 
cell lines. Considering p300 is one of the main acetyltransferases of H3K18ac 
and H3K27ac, we proposed that p300 is required for the acetylation of H3K18 
and H3K27 at super-enhancers associated with the dominant MYC family gene 
in SCLC cell. We chose two regions of the published MYC super-enhancer in 
H82 cell as examples and performed H3K18ac and H3K27ac ChIP-qPCR in 
p300-depleted and NT control H82 cells. Significant decrease of H3K27ac level 
at both regions was observed in p300-depleted cells (Figure 34B). The depletion 
of p300 also led to a severe drop of H3K18ac level at SE1 region. The decrease 
of both histone markers at MYC super-enhancers resulted from p300 depletion is 
consistent with the reduced MYC expression. Taken together, we found p300 is 
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required for sustaining the histone acetylation and expression of super-
enhancers-associated oncogenes in SCLC cells. 
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Figure 33. Expression activation of the dominant MYC family gene is 
dependent on p300.  
(A) RT-qPCR analysis of 3 MYC family genes in H69 and H82 cells. (B) RT-
qPCR analysis of 3 MYC family genes in control and p300/CBP-depleted H69 
and H82 cells.   
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Figure 34. Histone acetylation at MYC super-enhancer regions requires 
p300.  
(A) The genome-browser views of H3K27ac at MYC and MYCN super-enhancer 
regions. The raw data tracks are from Gene Expression Omnibus with the 
accession number GSE62614 (153). The red lines indicate the sites for ChIP-
qPCR in (B). SE: super-enhancer. (B) qPCR analysis of the H3K27ac level at two 
MYC super-enhancer regions.  
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4.3 Conclusions 
In this study, we show that p300 and CBP are overexpressed in both 
murine and human SCLC cells. Depletion of p300, but not CBP, impedes SCLC 
cell proliferation. Both p300 and CBP are required for sustaining the expression 
of oncogenes, for example, the MYC family genes, in SCLC cells. However, the 
expression of the dominant MYC family gene that is associated with super-
enhancers shows more dependency on p300 than CBP. Consistently, p300, but 
not CBP, is essential for maintenance of SCLC cell growth. 
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4.4 Discussion 
SCLC is the most aggressive subtype of lung cancer with an unmet need 
for effective treatment (182). The molecular basis of this disease is poorly 
understood. Here we found that p300 is required for the proliferation of both 
murine and human SCLC cells. The proliferation defect caused by p300 
depletion was observed in all SCLC cell lines tested. However, more cell lines 
need to be tested before we can conclude that p300 dependency is a ubiquitous 
mechanism in SCLC, a highly heterogeneous disease. It will also be important to 
test in the future whether p300 depletion also attenuates SCLC tumor growth in a 
xenograft or allograft model. Importantly, p300 depletion does not dramatically 
affect the proliferation of NSCLC cells or normal lung epithelial cell, implying that 
inhibiting p300 may be a potential SCLC treatment method with low toxicity to 
normal lung cell.  
Despite of the high sequence similarity between p300 and CBP, CBP is 
not required for cell proliferation in the SCLC cell lines tested. Because of the 
relatively high mutation rate (13~15%) of CREBBP/EP300 in SCLC (95, 136), it 
has been previously predicted that both CREBBP and EP300 are tumor 
suppressor genes (183). Most CREBBP alterations are nonsense mutations, 
deletions, frameshifts and translocations (Figure 5B), which are likely loss-of-
function. Consistent with the mutation status of CREBBP, the laboratory of Dr. 
David MacPherson recently reported that lung neuroendocrine-specific triple 
knockout of Trp53, Rb1 and Crebbp in mice accelerates SCLC tumorigenesis 
compared with Trp53 Rb1 double knockout mice, indicating Crebbp is a tumor 
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suppressor gene in murine SCLC (184). However, this paper did not mention the 
role of p300 in SCLC. In fact, the mutation pattern of EP300 in SCLC is distinct 
from that of CREBBP. The majority of EP300 alterations are missense mutations 
with unknown consequences, though only a few of mutations within p300 HAT 
domain have been confirmed to reduce HAT activity (95). Therefore, the mutation 
status of EP300 in SCLC does not conflict with our results that p300 is required 
in maintaining the continuous growth of SCLC cells.  
An explanation for the functional differences between p300 and CBP in 
SCLC may be that they target different genes (185). In H69 and H82 cells, 
activation of the dominant MYC family gene that is associated with super-
enhancers relies more on p300 than on CBP, which may reflect the differences in 
their target genes. Unfortunately, we only have a small amount of preliminary 
data on how p300 and CBP regulate oncogenes in SCLC cells. RNA-seq and 
H3K27ac ChIP-seq analysis using control cell, p300- or CBP-depleted cells will 
provide more comprehensive information to help us understand the molecular 
basis of the p300-dependency in SCLC cell proliferation in the future.  
Overall, although still preliminary, our data start to shed light on the critical 
functions of p300 in SCLC. Future studies will bring further insights into the 
molecular mechanisms of SCLC maintenance and evaluate p300 inhibition as a 
new therapeutic strategy for SCLC patients.  
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Chapter 5. Future Directions 
 
5.1 Determining the physiological importance of p300 ZZ domain 
p300 is a key transcription coactivator important to both development and 
diseases. Our findings that the ZZ domain is required for both chromatin binding 
and histone acetylation, the basic molecular functions of p300, suggesting that 
the ZZ domain is likely critical for p300 to exert its functions in both physiological 
and pathological settings. It is particularly interesting to me to determine the 
functional importance of the ZZ domain in human cancers. 
Although there is no cancer-related mutation hotspot in p300 ZZ domain 
reported in TCGA, we did find dozens of genetic mutations occurring in the ZZ 
domain coding regions, albeit with low frequency, from cBioPortal 
(https://www.cbioportal.org) (119, 120) and Catalogue of Somatic Mutations in 
Cancer (COSMIC, https://cancer.sanger.ac.uk/cosmic) (186). All up-to-date 
mutations located in p300 ZZ domain are listed in Table 6 and Figure 35A. The 
effect of those mutations on p300 ZZ’s function is currently unknown. 
In our preliminary studies, we expressed and purified recombinant ZZ 
domain mutants mimicking a few TCGA mutations, including R1680C/H, W1681* 
and D1688H (Figure 35B) and tested their histone-binding activity. Histone 
peptide pull-down assays showed that the H3-binding activity is reduced in 
R1680C and W1681A and abolished in the D1688K mutant (Figure 35C). These 
preliminary data suggest that cancer-related mutations can abrogate the function 
of ZZ, implying the histone-binding activity of p300 ZZ domain is indeed 
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important to tumorigenesis. In the future, it will be interesting to study the function 
of p300 ZZ domain in tumorigenesis using a proper cancer model. For instance, 
the colon cancer mutation of ZZ domain, R1680C, can be introduced into 
endogenous EP300 gene by CRISPR/Cas9-mediated DNA cutting followed by 
homology-directed repair using single-stranded oligodeoxynucleotides in colon 
epithelial cells. Single clones containing a R1680C point mutation will be selected 
and examined for their cell growth and survival in culture. We’ll also establish 
xenograft models using those cells for measuring tumor growth in vivo. 
Mechanistically, the epigenome and transcriptome of parental and ZZ-mutated 
cells will be assessed by p300 and histone ChIP-seq and RNA-seq, respectively. 
The ZZ domain is required for p300-dependent H3K18 and H3K27 
acetylation and the BRD is required for the acetylation of all lysine residues on 
H3 and H4 by p300. Importantly, these two domains seem to cooperate in 
regulating the HAT activity of p300. The inhibitors of p300 BRD showed good 
anti-cancer effect in hematopoietic malignancies (43, 118). In the future, we also 
plan to determine whether ZZ mutations can sensitize cells to those BRD 
inhibitor, which will be beneficial to the development of targeted therapies. 
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Sample ID Cancer Study Gene AA change Type 
MFE296 cell line CCLE (Novartis/Broad 2012) EP300 R1665H Missense 
ATLL_A-01 Lymphoma/leukemia (COSMIC) EP300 T1669I Missense 
ATL014 Lymphoma/leukemia (COSMIC) EP300 T1669I Missense 
TCGA-BG-A0MG-01 Uterine (TCGA) EP300 E1672* Nonsense 
OSCC-GB_01670111 Oral (COSMIC) EP300 E1672* Nonsense 
ESCC_E11 Esophagus (COSMIC) EP300 C1673Y Missense 
MBC_71 MBL (Sickkids 2016) EP300 E1678Q Missense 
Pat_59_B Melanoma (COSMIC) EP300 T1679I Missense 
TCGA-DM-A1D0-01 Colon (TCGA) EP300 R1680H Missense 
TCGA-F5-6813-01 Colon (TCGA) EP300 R1680H Missense 
PLK106Ca Colon (COSMIC) EP300 R1680C Missense 
TCGA-ZR-A9CJ-01 Esophagus (TCGA) EP300 R1680C Missense 
PD8141a AML (COSMIC) EP300 W1681* Nonsense 
ATL359 Lymphoma/leukemia (COSMIC) EP300 C1683Y Missense 
coadread_dfci_2016_2768 Colorectal (DFCI 2016) EP300 V1685I Missense 
T2768 Colon (COSMIC) EP300 V1685I Missense 
Pat_24_Pre Melanoma (Broad 2012) EP300 C1686Y Missense 
PAJMVC Kidney (COSMIC) EP300 C1686* Nonsense 
ID32 AML (COSMIC) EP300 C1686fs FS del 
SW948 cell line CCLE (Novartis/Broad 2012) EP300 X1687_splice Splice 
MTS-T0713 Breast (METABRIC) EP300 D1688H Missense 
TCGA-P3-A5Q5-01 Head & neck (TCGA) EP300 D1688H Missense 
TCGA-GR-A4D6-01 DLBC (TCGA) EP300 T1694A Missense 
HCT-116 cell line NCI-60 EP300 N1700fs FS del 
P-0003104-T01-IM5 MSK-IMPACT EP300 H1703Y Missense 
P-0010591-T01-IM5 MSK-IMPACT EP300 E1706* Nonsense 
 
Table 6. Mutations in p300 ZZ domain occurring in cancers. 
Data are collected from cBioPortal (www.cbioportal.org) (119, 120) and COSMIC 
(https://cancer.sanger.ac.uk/cosmic) (186). The diagram view of these listed 
mutations is in Figure 35A. 	
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Figure 35. Mutations of p300 ZZ domain occurring in cancers. 
(A) The diagram view of all the mutations of p300 ZZ domain occurring in 
cancers (also listed in Table 6). Diagram is generated using the online tool 
ProteinPaint (https://pecan.stjude.cloud/proteinpaint) (187). (B) Examples of 
p300 ZZ domain mutations that occur in cancers. (C) Peptide pull-down assays 
using wild type and mutated p300 ZZ domain. 
  
119	
	
5.2 Determining the role of p300 in SCLC maintenance 
Our preliminary data has shown that p300 is necessary to SCLC cell 
proliferation in cell culture. This is an interesting observation, however, much 
more need to be done to reveal the role of p300 in SCLC maintenance. It would 
be of great interest to determine in the future whether p300 depletion impedes 
SCLC tumor growth in xenograft or allograft models. We can perform RNA-seq 
and ChIP-seq to further examine the transcriptomic and epigenomic changes 
resulted from p300, CBP, or double depletions. It is anticipated that depletion of 
p300, CBP or both will lead to a drastic decrease in the expression of oncogenes 
associated with super-enhancers in SCLC tumors.  
Interestingly, a recent report shows that SCLC cells are not sensitive to A-
485, a potent small molecule inhibitor targeting p300/CBP HAT domain (15), 
indicating that the function of p300 in SCLC cell proliferation may not require the 
HAT activity. Indeed, p300 is essential for the assembly of a transcription 
activation complex using protein-interaction domains, which may contribute to 
disease maintenance independent of its HAT activity. This makes it urgent to 
identify the protein domains or minimal regions of p300 that are critical for its 
biological functions in SCLC. To identify such essential domains, we will perform 
a CRISPR/Cas9-based dropout screening in SCLC cells using a tilling gRNA 
library targeting the EP300 gene exons encoding the full-length p300 protein. 
The gRNAs targeting critical domains or regions are expected to have 
significantly lower enrichment. After the critical domains/regions are identified, 
rescue assays will be performed using constructs containing the deletion of each 
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critical domain or region in p300-depleted SCLC cells. If specific inhibitors for the 
critical domains are available, we will also test whether SCLC cells are sensitive 
to those compounds. 
Collectively, these studies will depict a detailed picture of the molecular 
mechanisms of p300 and extend our understanding of critical roles of p300 in 
important biological processes. Furthermore, elucidating the role of p300 in 
SCLC will help to bring insights into the molecular basis of SCLC maintenance 
and may provide p300 as a new therapeutic target for treatment of SCLC. 
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